ALPHAFORGE RESEARCH · COMPANY FILE · HEALTHCARE SERVICES & DEVICES

$GKOS

GLAUKOS Corp · NYSE · SIC 3841 · CIK 1192448 · revision 4 as of 2026-09-19

All companies · Free for people and agents · JSON · Download model CSV · Operating scenarios

Business

Glaukos sells ophthalmic therapies and devices for glaucoma and corneal disease. iDose is part of US glaucoma revenue; Epioxa is part of corneal health. Adoption depends on physician use, patient access and reimbursement. Commercial launches and clinical development consume cash before potential scale benefits, while a new manufacturing and research facility adds a multi-year investment requirement.

Three drivers

iDose and Epioxa adoption, access and product mix
Commercial and clinical spending including equity compensation
Collections, inventory and manufacturing construction cash

Thesis

Our view

New products can expand sales rapidly, but adoption must pay for commercial infrastructure, ongoing R&D and manufacturing investment. The relevant evidence is cash generation after these uses. Management adjusted earnings retain ordinary equity compensation and acquired research expense, so treating every adjustment as an SBC exclusion would misstate the economics.

What changes it

Compare product uptake with receivable collections and access conditions. Improve confidence if operating leverage persists after launch spending and construction; reduce it if collection or reimbursement friction outpaces adoption.

Scenario ranges

Explicit downside/base/upside business assumptions; not price targets, probabilities or historical market-memory bands.

Model · 8 fiscal quarters (last eight)

Fiscal quarter	2024Q3 2024-09-30	2024Q4 2024-12-31	2025Q1 2025-03-31	2025Q2 2025-06-30	2025Q3 2025-09-30	2025Q4 2025-12-31	2026Q1 2026-03-31	2026Q2 2026-06-30
Revenue ($M)	96.7¹	105.5†²	106.7³	124.1⁴	133.5¹	143.1†²	150.6³	185.6⁴
Gross profit ($M)	74.1⁵	76.9†⁶	82.3⁷	97.2⁸	104.7⁵	-1.5†⁶	117.2⁷	151.6⁸
Operating income ($M)	-24.7⁹	-28.7†¹⁰	-20.7¹¹	-22.7¹²	-16.4⁹	-139.9†¹⁰	-19.9¹¹	-17.3¹²
Net income ($M)	-21.4¹³	-33.6†¹⁴	-18.1¹⁵	-19.7¹⁶	-16.2¹³	-133.7†¹⁴	-19.8¹⁵	-18.4¹⁶
EPS, diluted ($)	-0.39¹⁷	—	-0.32¹⁸	-0.34¹⁹	-0.28¹⁷	—	-0.34¹⁸	-0.31¹⁹
Diluted shares (M)	55.0²⁰	—	56.6²¹	57.2²²	57.4²⁰	—	58.0²¹	58.8²²
Cash ($M)	100.1²³	169.6²⁴	114.3²⁵	100.8²⁶	98.2²⁷	90.8²⁸	104.2²⁹	114.5²⁸
Long-term debt ($M)	—	—	—	—	—	—	—	—
Cash from operations ($M)	-9.6†³⁰	0.5†³¹	-18.5³²	7.0†³³	-10.1†³⁰	6.8†³¹	-12.5³²	14.8†³³
Capex ($M)	1.4†³⁴	1.7†³⁵	1.9³⁶	1.2†³⁷	1.6†³⁴	2.9†³⁵	4.0³⁶	2.7†³⁷
Free cash flow ($M)	-11.0†³⁸	-1.2†³⁹	-20.5†⁴⁰	5.8†⁴¹	-11.7†³⁸	3.9†³⁹	-16.5†⁴⁰	12.1†⁴¹

† derived (Q4 = fiscal year minus the first three quarters; year-to-date cash flows differenced; FCF = CFO − capex). Superscripts are the provenance notes below.

Estimates · base scenario

Period	Revenue ($M)	EPS ($)	As of	Basis
2026Q3	166.3	—	2026-09-19	Desk base scenario. Revenue basis: Revenue ($M). Calculated from the operating-model inputs below; not consensus or company guidance.
2026Q4	187.5	—	2026-09-19	Desk base scenario. Revenue basis: Revenue ($M). Calculated from the operating-model inputs below; not consensus or company guidance.
2027Q1	209.4	—	2026-09-19	Desk base scenario. Revenue basis: Revenue ($M). Calculated from the operating-model inputs below; not consensus or company guidance.
2027Q2	227.6	—	2026-09-19	Desk base scenario. Revenue basis: Revenue ($M). Calculated from the operating-model inputs below; not consensus or company guidance.

Ophthalmic launch growth after research and manufacturing investment

Operating scenarios · reviewed 2026-09-19 · USD millions unless labeled otherwise · our assumptions, not consensus

Anchor H2 sales to annual guidance less actual H1. Separate iDose, other US glaucoma, international glaucoma, Epioxa and other corneal products; Epioxa is inside corneal health, not an incremental franchise. Extend each stream from its own H2 annualized run rate. Non-GAAP margins and operating costs retain ordinary stock compensation and acquired research charges. Bridge to GAAP using acquired amortization and specific costs, then to cash with receivables, inventory, manufacturing capex, finance leases and equity-award payments.

Reported anchors and guidance

Measure	Period	Value	Basis
2026 net sales guidance midpoint	FY2026	690.00	derived. Calculated midpoint of the company range; not an additional company forecast.
q2 idose	June/July 2026	74.00	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
q2 epioxa	June/July 2026	11.00	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
q2 us glaucoma	June/July 2026	118.50	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
q2 corneal	June/July 2026	30.40	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
H1 non gaap op	H1 2026	-18.08	reported. Reported consolidated amount, converted from thousands to millions. Source · 2026-07-29
H1 operating income	H1 2026	-37.12	reported. Reported consolidated amount, converted from thousands to millions. Source · 2026-07-29
H1 sbc	H1 2026	48.01	reported. Reported consolidated amount, converted from thousands to millions. Source · 2026-07-29
q2 award trigger	June/July 2026	15.00	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
H1 cfo	H1 2026	2.30	reported. Reported consolidated amount, converted from thousands to millions. Source · 2026-07-29
H1 CFO less PP&E	H1 2026	-4.40	derived. Historical PP&E scope; no 2026 H1 real-estate acquisition.
H1 cash after other cash uses	H1 2026	-17.34	derived. Before equity issuance proceeds.
Unrestricted cash and short-term investments	June 2026	286.23	derived. Excludes restricted cash; finance lease claims remain.
restricted cash	June/July 2026	3.12	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
finance lease liability	June/July 2026	67.34	reported. Company June-quarter reference; product/franchise and award-trigger figures rounded. Source · 2026-07-29
huntsville multiyear	June/July 2026	80.00	reported. Rounded company disclosure; manufacturing investment is MORE THAN $80M over multiple years. Source · 2026-07-29

Downside scenario

Period	Operating cash flow ($M)	CFO less capex ($M)	PP&E and construction cash ($M)	Revenue ($M)	Non-GAAP operating income proxy ($M)	GAAP gross profit proxy ($M)	GAAP operating income proxy ($M)	Cash after capex and other cash uses ($M)
2026Q3	-32.62	-42.62	10.00	146.84	-29.59	115.11	-38.39	-49.47
2026Q4	-26.11	-39.11	13.00	165.58	-21.27	130.48	-30.07	-45.96
2027Q1	-32.04	-47.04	15.00	159.05	-30.68	126.22	-36.88	-53.89
2027Q2	-28.82	-46.82	18.00	172.88	-26.39	137.56	-32.59	-53.67
FY2026	-56.43	-86.13	29.70	648.60	-68.94	514.41	-105.59	-112.77
FY2027	-121.88	-193.88	72.00	691.52	-114.15	550.25	-138.95	-221.28

Base scenario

Period	Operating cash flow ($M)	CFO less capex ($M)	PP&E and construction cash ($M)	Revenue ($M)	Non-GAAP operating income proxy ($M)	GAAP gross profit proxy ($M)	GAAP operating income proxy ($M)	Cash after capex and other cash uses ($M)
2026Q3	1.55	-6.45	8.00	166.29	-2.48	135.22	-11.28	-13.30
2026Q4	11.78	0.78	11.00	187.52	8.66	153.16	-0.14	-6.07
2027Q1	26.97	13.97	13.00	209.37	23.32	172.72	17.12	7.12
2027Q2	34.92	19.92	15.00	227.57	31.90	188.10	25.70	13.07
FY2026	15.63	-10.07	25.70	690.00	-11.90	557.20	-48.55	-36.71
FY2027	133.57	71.57	62.00	910.30	119.50	752.40	94.70	44.17

Upside scenario

Period	Operating cash flow ($M)	CFO less capex ($M)	PP&E and construction cash ($M)	Revenue ($M)	Non-GAAP operating income proxy ($M)	GAAP gross profit proxy ($M)	GAAP operating income proxy ($M)	Cash after capex and other cash uses ($M)
2026Q3	24.20	15.20	9.00	189.00	16.54	157.24	7.74	8.35
2026Q4	37.59	25.59	12.00	213.12	30.38	177.99	21.58	18.74
2027Q1	81.84	67.84	14.00	270.21	75.56	228.18	69.36	60.99
2027Q2	94.73	78.73	16.00	293.70	88.85	248.38	82.65	71.88
FY2026	64.08	36.39	27.70	738.30	28.84	604.05	-7.81	9.75
FY2027	372.60	304.60	68.00	1,174.81	347.09	993.53	322.29	277.20

All inputs and formulas — reproduce this model

Input / calculation	Period / case	Value / unit	Evidence or assumption
H1 revenue h1_revenue	H1 2026 / shared	336.18 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 gross profit h1_gross_profit	H1 2026 / shared	268.83 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 operating income h1_operating_income	H1 2026 / shared	-37.12 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 non gaap op h1_non_gaap_op	H1 2026 / shared	-18.08 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 cfo h1_cfo	H1 2026 / shared	2.30 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 capex h1_capex	H1 2026 / shared	6.70 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 sbc h1_sbc	H1 2026 / shared	48.01 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 da h1_da	H1 2026 / shared	20.67 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 receivable use h1_receivable_use	H1 2026 / shared	31.91 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 life insurance h1_life_insurance	H1 2026 / shared	3.89 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 award cash h1_award_cash	H1 2026 / shared	8.41 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 lease principal h1_lease_principal	H1 2026 / shared	0.64 USD_millions	reported: Reported consolidated amount, converted from thousands to millions. Primary source · 2026-07-29
H1 CFO less PP&E h1_fcf	H1 2026 / shared	-4.40 USD_millions	derived: Historical PP&E scope; no 2026 H1 real-estate acquisition. Formula: subtract(h1_cfo, h1_capex).
H1 insurance, awards and finance lease cash h1_other_cash	H1 2026 / shared	12.94 USD_millions	derived: Distinct investing and financing outflows. Formula: sum(h1_life_insurance, h1_award_cash, h1_lease_principal).
H1 cash after other cash uses h1_cash_after_claims	H1 2026 / shared	-17.34 USD_millions	derived: Before equity issuance proceeds. Formula: subtract(h1_fcf, h1_other_cash).
cash cash	June/July 2026 / shared	114.48 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
investments investments	June/July 2026 / shared	171.74 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
restricted cash restricted_cash	June/July 2026 / shared	3.12 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
finance lease liability finance_lease_liability	June/July 2026 / shared	67.34 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 idose q2_idose	June/July 2026 / shared	74.00 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 epioxa q2_epioxa	June/July 2026 / shared	11.00 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 us glaucoma q2_us_glaucoma	June/July 2026 / shared	118.50 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 international q2_international	June/July 2026 / shared	36.60 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 corneal q2_corneal	June/July 2026 / shared	30.40 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 sbc q2_sbc	June/July 2026 / shared	28.86 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
q2 award trigger q2_award_trigger	June/July 2026 / shared	15.00 USD_millions	reported: Company June-quarter reference; product/franchise and award-trigger figures rounded. Primary source · 2026-07-29
huntsville multiyear huntsville_multiyear	June/July 2026 / shared	80.00 USD_millions	reported: Rounded company disclosure; manufacturing investment is MORE THAN $80M over multiple years. Primary source · 2026-07-29
Unrestricted cash and short-term investments liquidity	June 2026 / shared	286.23 USD_millions	derived: Excludes restricted cash; finance lease claims remain. Formula: sum(cash, investments).
2026 net sales guidance low annual_guide_low	FY2026 / shared	680.00 USD_millions	management guidance: Company guidance; not a desk forecast. Primary source · 2026-07-29
2026 net sales guidance high annual_guide_high	FY2026 / shared	700.00 USD_millions	management guidance: Company guidance; not a desk forecast. Primary source · 2026-07-29
Midpoint divisor two	Model / shared	200.0% ratio	assumption: Arithmetic constant.
2026 net sales guidance endpoint sum annual_guide_sum	FY2026 / shared	1,380.00 USD_millions	derived: Arithmetic intermediate. Formula: sum(annual_guide_low, annual_guide_high).
2026 net sales guidance midpoint annual_guide	FY2026 / shared	690.00 USD_millions	derived: Calculated midpoint of the company range; not an additional company forecast. Formula: divide(annual_guide_sum, two).
Annual sales / guidance midpoint downside_delivery	FY2026 / downside	94.0% ratio	assumption: Desk delivery and market-access sensitivity.
Annual revenue scenario downside_target	FY2026 / downside	648.60 USD_millions	derived: Nominal revenue including FX. Formula: multiply(annual_guide, downside_delivery).
Remaining H2 revenue downside_h2	H2 2026 / downside	312.42 USD_millions	derived: Annual scenario less reported H1. Formula: subtract(downside_target, h1_revenue).
Share of H2 sales downside_2026q3_h2_weight	2026Q3 / downside	47.0% ratio	assumption: Desk assumption, not company guidance.
Revenue downside_2026q3_revenue	2026Q3 / downside	146.84 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(downside_h2, downside_2026q3_h2_weight).
idose mix downside_2026q3_idose_mix	2026Q3 / downside	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2026q3_idose	2026Q3 / downside	63.14 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q3_revenue, downside_2026q3_idose_mix).
us_other mix downside_2026q3_us_other_mix	2026Q3 / downside	24.5% ratio	assumption: Desk assumption, not company guidance.
us other revenue downside_2026q3_us_other	2026Q3 / downside	35.98 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q3_revenue, downside_2026q3_us_other_mix).
international mix downside_2026q3_international_mix	2026Q3 / downside	21.0% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2026q3_international	2026Q3 / downside	30.84 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q3_revenue, downside_2026q3_international_mix).
corneal mix downside_2026q3_corneal_mix	2026Q3 / downside	11.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue downside_2026q3_corneal	2026Q3 / downside	16.89 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q3_revenue, downside_2026q3_corneal_mix).
Epioxa share of corneal downside_2026q3_epioxa_mix	2026Q3 / downside	55.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue downside_2026q3_epioxa	2026Q3 / downside	9.29 USD_millions	derived: Subset of corneal health. Formula: multiply(downside_2026q3_corneal, downside_2026q3_epioxa_mix).
Other corneal revenue downside_2026q3_corneal_other	2026Q3 / downside	7.60 USD_millions	derived: No Epioxa double counting. Formula: subtract(downside_2026q3_corneal, downside_2026q3_epioxa).
Non-GAAP gross margin downside_2026q3_ng_gm	2026Q3 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2026q3_ng_gross_profit	2026Q3 / downside	120.41 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2026q3_revenue, downside_2026q3_ng_gm).
Acquired amortization in COGS downside_2026q3_acquired_amort	2026Q3 / downside	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2026q3_gross_profit	2026Q3 / downside	115.11 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2026q3_ng_gross_profit, downside_2026q3_acquired_amort).
SG&A excluding stock compensation downside_2026q3_sg_cash	2026Q3 / downside	84.00 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2026q3_sg_sbc	2026Q3 / downside	13.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2026q3_sg	2026Q3 / downside	97.00 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2026q3_sg_cash, downside_2026q3_sg_sbc).
R&D including equity compensation downside_2026q3_rd	2026Q3 / downside	53.00 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2026q3_ipr	2026Q3 / downside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2026q3_ng_opex	2026Q3 / downside	150.00 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2026q3_sg, downside_2026q3_rd, downside_2026q3_ipr).
Non-GAAP operating income downside_2026q3_non_gaap_op	2026Q3 / downside	-29.59 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2026q3_ng_gross_profit, downside_2026q3_ng_opex).
Specific cash legal and integration costs downside_2026q3_special	2026Q3 / downside	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2026q3_op_before_special	2026Q3 / downside	-34.89 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2026q3_non_gaap_op, downside_2026q3_acquired_amort).
GAAP operating income downside_2026q3_operating_income	2026Q3 / downside	-38.39 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2026q3_op_before_special, downside_2026q3_special).
R&D and COGS equity compensation downside_2026q3_other_sbc	2026Q3 / downside	6.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2026q3_sbc	2026Q3 / downside	19.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2026q3_sg_sbc, downside_2026q3_other_sbc).
Other depreciation downside_2026q3_depreciation	2026Q3 / downside	3.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2026q3_net_interest	2026Q3 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2026q3_cash_before_uses	2026Q3 / downside	-9.89 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2026q3_operating_income, downside_2026q3_sbc, downside_2026q3_acquired_amort, downside_2026q3_depreciation, downside_2026q3_net_interest).
Net working-capital use / sales downside_2026q3_wc_ratio	2026Q3 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2026q3_wc	2026Q3 / downside	22.03 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2026q3_revenue, downside_2026q3_wc_ratio).
Cash taxes downside_2026q3_tax	2026Q3 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2026q3_operating_cash_uses	2026Q3 / downside	22.73 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2026q3_wc, downside_2026q3_tax).
Operating cash flow downside_2026q3_cfo	2026Q3 / downside	-32.62 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2026q3_cash_before_uses, downside_2026q3_operating_cash_uses).
PP&E including construction spending downside_2026q3_capex	2026Q3 / downside	10.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2026q3_fcf	2026Q3 / downside	-42.62 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2026q3_cfo, downside_2026q3_capex).
Company-owned life insurance purchases downside_2026q3_life_insurance	2026Q3 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2026q3_award_cash	2026Q3 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2026q3_lease_principal	2026Q3 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2026q3_other_cash	2026Q3 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2026q3_life_insurance, downside_2026q3_award_cash, downside_2026q3_lease_principal).
Cash after other cash uses downside_2026q3_cash_after_claims	2026Q3 / downside	-49.47 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2026q3_fcf, downside_2026q3_other_cash).
Share of H2 sales downside_2026q4_h2_weight	2026Q4 / downside	53.0% ratio	assumption: Desk assumption, not company guidance.
Revenue downside_2026q4_revenue	2026Q4 / downside	165.58 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(downside_h2, downside_2026q4_h2_weight).
idose mix downside_2026q4_idose_mix	2026Q4 / downside	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2026q4_idose	2026Q4 / downside	71.20 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q4_revenue, downside_2026q4_idose_mix).
us_other mix downside_2026q4_us_other_mix	2026Q4 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
us other revenue downside_2026q4_us_other	2026Q4 / downside	39.74 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q4_revenue, downside_2026q4_us_other_mix).
international mix downside_2026q4_international_mix	2026Q4 / downside	19.5% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2026q4_international	2026Q4 / downside	32.29 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q4_revenue, downside_2026q4_international_mix).
corneal mix downside_2026q4_corneal_mix	2026Q4 / downside	13.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue downside_2026q4_corneal	2026Q4 / downside	22.35 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(downside_2026q4_revenue, downside_2026q4_corneal_mix).
Epioxa share of corneal downside_2026q4_epioxa_mix	2026Q4 / downside	72.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue downside_2026q4_epioxa	2026Q4 / downside	16.09 USD_millions	derived: Subset of corneal health. Formula: multiply(downside_2026q4_corneal, downside_2026q4_epioxa_mix).
Other corneal revenue downside_2026q4_corneal_other	2026Q4 / downside	6.26 USD_millions	derived: No Epioxa double counting. Formula: subtract(downside_2026q4_corneal, downside_2026q4_epioxa).
Non-GAAP gross margin downside_2026q4_ng_gm	2026Q4 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2026q4_ng_gross_profit	2026Q4 / downside	135.78 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2026q4_revenue, downside_2026q4_ng_gm).
Acquired amortization in COGS downside_2026q4_acquired_amort	2026Q4 / downside	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2026q4_gross_profit	2026Q4 / downside	130.48 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2026q4_ng_gross_profit, downside_2026q4_acquired_amort).
SG&A excluding stock compensation downside_2026q4_sg_cash	2026Q4 / downside	87.36 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2026q4_sg_sbc	2026Q4 / downside	13.60 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2026q4_sg	2026Q4 / downside	100.96 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2026q4_sg_cash, downside_2026q4_sg_sbc).
R&D including equity compensation downside_2026q4_rd	2026Q4 / downside	54.59 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2026q4_ipr	2026Q4 / downside	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2026q4_ng_opex	2026Q4 / downside	157.05 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2026q4_sg, downside_2026q4_rd, downside_2026q4_ipr).
Non-GAAP operating income downside_2026q4_non_gaap_op	2026Q4 / downside	-21.27 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2026q4_ng_gross_profit, downside_2026q4_ng_opex).
Specific cash legal and integration costs downside_2026q4_special	2026Q4 / downside	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2026q4_op_before_special	2026Q4 / downside	-26.57 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2026q4_non_gaap_op, downside_2026q4_acquired_amort).
GAAP operating income downside_2026q4_operating_income	2026Q4 / downside	-30.07 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2026q4_op_before_special, downside_2026q4_special).
R&D and COGS equity compensation downside_2026q4_other_sbc	2026Q4 / downside	6.70 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2026q4_sbc	2026Q4 / downside	20.30 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2026q4_sg_sbc, downside_2026q4_other_sbc).
Other depreciation downside_2026q4_depreciation	2026Q4 / downside	3.40 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2026q4_net_interest	2026Q4 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2026q4_cash_before_uses	2026Q4 / downside	-0.57 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2026q4_operating_income, downside_2026q4_sbc, downside_2026q4_acquired_amort, downside_2026q4_depreciation, downside_2026q4_net_interest).
Net working-capital use / sales downside_2026q4_wc_ratio	2026Q4 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2026q4_wc	2026Q4 / downside	24.84 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2026q4_revenue, downside_2026q4_wc_ratio).
Cash taxes downside_2026q4_tax	2026Q4 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2026q4_operating_cash_uses	2026Q4 / downside	25.54 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2026q4_wc, downside_2026q4_tax).
Operating cash flow downside_2026q4_cfo	2026Q4 / downside	-26.11 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2026q4_cash_before_uses, downside_2026q4_operating_cash_uses).
PP&E including construction spending downside_2026q4_capex	2026Q4 / downside	13.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2026q4_fcf	2026Q4 / downside	-39.11 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2026q4_cfo, downside_2026q4_capex).
Company-owned life insurance purchases downside_2026q4_life_insurance	2026Q4 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2026q4_award_cash	2026Q4 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2026q4_lease_principal	2026Q4 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2026q4_other_cash	2026Q4 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2026q4_life_insurance, downside_2026q4_award_cash, downside_2026q4_lease_principal).
Cash after other cash uses downside_2026q4_cash_after_claims	2026Q4 / downside	-45.96 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2026q4_fcf, downside_2026q4_other_cash).
Prior H2 idose downside_2027q1_idose_h2	2027Q1 / downside	134.34 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_idose, downside_2026q4_idose).
Half-year annualization downside_2027q1_idose_annualize	2027Q1 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q1_idose_growth	2027Q1 / downside	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q1_idose_season	2027Q1 / downside	23.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2027q1_idose	2027Q1 / downside	71.07 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q1_idose_h2, downside_2027q1_idose_annualize, downside_2027q1_idose_growth, downside_2027q1_idose_season).
Prior H2 us_other downside_2027q1_us_other_h2	2027Q1 / downside	75.71 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_us_other, downside_2026q4_us_other).
Half-year annualization downside_2027q1_us_other_annualize	2027Q1 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q1_us_other_growth	2027Q1 / downside	100.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q1_us_other_season	2027Q1 / downside	23.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue downside_2027q1_us_other	2027Q1 / downside	34.83 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q1_us_other_h2, downside_2027q1_us_other_annualize, downside_2027q1_us_other_growth, downside_2027q1_us_other_season).
Prior H2 international downside_2027q1_international_h2	2027Q1 / downside	63.12 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_international, downside_2026q4_international).
Half-year annualization downside_2027q1_international_annualize	2027Q1 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q1_international_growth	2027Q1 / downside	105.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q1_international_season	2027Q1 / downside	23.0% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2027q1_international	2027Q1 / downside	30.49 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q1_international_h2, downside_2027q1_international_annualize, downside_2027q1_international_growth, downside_2027q1_international_season).
Prior H2 epioxa downside_2027q1_epioxa_h2	2027Q1 / downside	25.38 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_epioxa, downside_2026q4_epioxa).
Half-year annualization downside_2027q1_epioxa_annualize	2027Q1 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q1_epioxa_growth	2027Q1 / downside	145.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q1_epioxa_season	2027Q1 / downside	23.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue downside_2027q1_epioxa	2027Q1 / downside	16.93 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q1_epioxa_h2, downside_2027q1_epioxa_annualize, downside_2027q1_epioxa_growth, downside_2027q1_epioxa_season).
Prior H2 corneal_other downside_2027q1_corneal_other_h2	2027Q1 / downside	13.86 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_corneal_other, downside_2026q4_corneal_other).
Half-year annualization downside_2027q1_corneal_other_annualize	2027Q1 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q1_corneal_other_growth	2027Q1 / downside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q1_corneal_other_season	2027Q1 / downside	23.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue downside_2027q1_corneal_other	2027Q1 / downside	5.74 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q1_corneal_other_h2, downside_2027q1_corneal_other_annualize, downside_2027q1_corneal_other_growth, downside_2027q1_corneal_other_season).
Revenue downside_2027q1_revenue	2027Q1 / downside	159.05 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(downside_2027q1_idose, downside_2027q1_us_other, downside_2027q1_international, downside_2027q1_epioxa, downside_2027q1_corneal_other).
Non-GAAP gross margin downside_2027q1_ng_gm	2027Q1 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2027q1_ng_gross_profit	2027Q1 / downside	130.42 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2027q1_revenue, downside_2027q1_ng_gm).
Acquired amortization in COGS downside_2027q1_acquired_amort	2027Q1 / downside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2027q1_gross_profit	2027Q1 / downside	126.22 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2027q1_ng_gross_profit, downside_2027q1_acquired_amort).
SG&A excluding stock compensation downside_2027q1_sg_cash	2027Q1 / downside	90.72 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2027q1_sg_sbc	2027Q1 / downside	14.20 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2027q1_sg	2027Q1 / downside	104.92 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2027q1_sg_cash, downside_2027q1_sg_sbc).
R&D including equity compensation downside_2027q1_rd	2027Q1 / downside	56.18 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2027q1_ipr	2027Q1 / downside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2027q1_ng_opex	2027Q1 / downside	161.10 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2027q1_sg, downside_2027q1_rd, downside_2027q1_ipr).
Non-GAAP operating income downside_2027q1_non_gaap_op	2027Q1 / downside	-30.68 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2027q1_ng_gross_profit, downside_2027q1_ng_opex).
Specific cash legal and integration costs downside_2027q1_special	2027Q1 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2027q1_op_before_special	2027Q1 / downside	-34.88 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2027q1_non_gaap_op, downside_2027q1_acquired_amort).
GAAP operating income downside_2027q1_operating_income	2027Q1 / downside	-36.88 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2027q1_op_before_special, downside_2027q1_special).
R&D and COGS equity compensation downside_2027q1_other_sbc	2027Q1 / downside	6.90 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2027q1_sbc	2027Q1 / downside	21.10 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2027q1_sg_sbc, downside_2027q1_other_sbc).
Other depreciation downside_2027q1_depreciation	2027Q1 / downside	3.60 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2027q1_net_interest	2027Q1 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2027q1_cash_before_uses	2027Q1 / downside	-7.48 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2027q1_operating_income, downside_2027q1_sbc, downside_2027q1_acquired_amort, downside_2027q1_depreciation, downside_2027q1_net_interest).
Net working-capital use / sales downside_2027q1_wc_ratio	2027Q1 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2027q1_wc	2027Q1 / downside	23.86 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2027q1_revenue, downside_2027q1_wc_ratio).
Cash taxes downside_2027q1_tax	2027Q1 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2027q1_operating_cash_uses	2027Q1 / downside	24.56 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2027q1_wc, downside_2027q1_tax).
Operating cash flow downside_2027q1_cfo	2027Q1 / downside	-32.04 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2027q1_cash_before_uses, downside_2027q1_operating_cash_uses).
PP&E including construction spending downside_2027q1_capex	2027Q1 / downside	15.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2027q1_fcf	2027Q1 / downside	-47.04 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2027q1_cfo, downside_2027q1_capex).
Company-owned life insurance purchases downside_2027q1_life_insurance	2027Q1 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2027q1_award_cash	2027Q1 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2027q1_lease_principal	2027Q1 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2027q1_other_cash	2027Q1 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2027q1_life_insurance, downside_2027q1_award_cash, downside_2027q1_lease_principal).
Cash after other cash uses downside_2027q1_cash_after_claims	2027Q1 / downside	-53.89 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2027q1_fcf, downside_2027q1_other_cash).
Prior H2 idose downside_2027q2_idose_h2	2027Q2 / downside	134.34 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_idose, downside_2026q4_idose).
Half-year annualization downside_2027q2_idose_annualize	2027Q2 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q2_idose_growth	2027Q2 / downside	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q2_idose_season	2027Q2 / downside	25.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2027q2_idose	2027Q2 / downside	77.25 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q2_idose_h2, downside_2027q2_idose_annualize, downside_2027q2_idose_growth, downside_2027q2_idose_season).
Prior H2 us_other downside_2027q2_us_other_h2	2027Q2 / downside	75.71 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_us_other, downside_2026q4_us_other).
Half-year annualization downside_2027q2_us_other_annualize	2027Q2 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q2_us_other_growth	2027Q2 / downside	100.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q2_us_other_season	2027Q2 / downside	25.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue downside_2027q2_us_other	2027Q2 / downside	37.86 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q2_us_other_h2, downside_2027q2_us_other_annualize, downside_2027q2_us_other_growth, downside_2027q2_us_other_season).
Prior H2 international downside_2027q2_international_h2	2027Q2 / downside	63.12 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_international, downside_2026q4_international).
Half-year annualization downside_2027q2_international_annualize	2027Q2 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q2_international_growth	2027Q2 / downside	105.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q2_international_season	2027Q2 / downside	25.0% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2027q2_international	2027Q2 / downside	33.14 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q2_international_h2, downside_2027q2_international_annualize, downside_2027q2_international_growth, downside_2027q2_international_season).
Prior H2 epioxa downside_2027q2_epioxa_h2	2027Q2 / downside	25.38 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_epioxa, downside_2026q4_epioxa).
Half-year annualization downside_2027q2_epioxa_annualize	2027Q2 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q2_epioxa_growth	2027Q2 / downside	145.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q2_epioxa_season	2027Q2 / downside	25.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue downside_2027q2_epioxa	2027Q2 / downside	18.40 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q2_epioxa_h2, downside_2027q2_epioxa_annualize, downside_2027q2_epioxa_growth, downside_2027q2_epioxa_season).
Prior H2 corneal_other downside_2027q2_corneal_other_h2	2027Q2 / downside	13.86 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_corneal_other, downside_2026q4_corneal_other).
Half-year annualization downside_2027q2_corneal_other_annualize	2027Q2 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q2_corneal_other_growth	2027Q2 / downside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q2_corneal_other_season	2027Q2 / downside	25.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue downside_2027q2_corneal_other	2027Q2 / downside	6.24 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q2_corneal_other_h2, downside_2027q2_corneal_other_annualize, downside_2027q2_corneal_other_growth, downside_2027q2_corneal_other_season).
Revenue downside_2027q2_revenue	2027Q2 / downside	172.88 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(downside_2027q2_idose, downside_2027q2_us_other, downside_2027q2_international, downside_2027q2_epioxa, downside_2027q2_corneal_other).
Non-GAAP gross margin downside_2027q2_ng_gm	2027Q2 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2027q2_ng_gross_profit	2027Q2 / downside	141.76 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2027q2_revenue, downside_2027q2_ng_gm).
Acquired amortization in COGS downside_2027q2_acquired_amort	2027Q2 / downside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2027q2_gross_profit	2027Q2 / downside	137.56 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2027q2_ng_gross_profit, downside_2027q2_acquired_amort).
SG&A excluding stock compensation downside_2027q2_sg_cash	2027Q2 / downside	94.08 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2027q2_sg_sbc	2027Q2 / downside	14.80 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2027q2_sg	2027Q2 / downside	108.88 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2027q2_sg_cash, downside_2027q2_sg_sbc).
R&D including equity compensation downside_2027q2_rd	2027Q2 / downside	57.77 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2027q2_ipr	2027Q2 / downside	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2027q2_ng_opex	2027Q2 / downside	168.15 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2027q2_sg, downside_2027q2_rd, downside_2027q2_ipr).
Non-GAAP operating income downside_2027q2_non_gaap_op	2027Q2 / downside	-26.39 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2027q2_ng_gross_profit, downside_2027q2_ng_opex).
Specific cash legal and integration costs downside_2027q2_special	2027Q2 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2027q2_op_before_special	2027Q2 / downside	-30.59 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2027q2_non_gaap_op, downside_2027q2_acquired_amort).
GAAP operating income downside_2027q2_operating_income	2027Q2 / downside	-32.59 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2027q2_op_before_special, downside_2027q2_special).
R&D and COGS equity compensation downside_2027q2_other_sbc	2027Q2 / downside	7.10 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2027q2_sbc	2027Q2 / downside	21.90 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2027q2_sg_sbc, downside_2027q2_other_sbc).
Other depreciation downside_2027q2_depreciation	2027Q2 / downside	3.80 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2027q2_net_interest	2027Q2 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2027q2_cash_before_uses	2027Q2 / downside	-2.19 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2027q2_operating_income, downside_2027q2_sbc, downside_2027q2_acquired_amort, downside_2027q2_depreciation, downside_2027q2_net_interest).
Net working-capital use / sales downside_2027q2_wc_ratio	2027Q2 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2027q2_wc	2027Q2 / downside	25.93 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2027q2_revenue, downside_2027q2_wc_ratio).
Cash taxes downside_2027q2_tax	2027Q2 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2027q2_operating_cash_uses	2027Q2 / downside	26.63 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2027q2_wc, downside_2027q2_tax).
Operating cash flow downside_2027q2_cfo	2027Q2 / downside	-28.82 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2027q2_cash_before_uses, downside_2027q2_operating_cash_uses).
PP&E including construction spending downside_2027q2_capex	2027Q2 / downside	18.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2027q2_fcf	2027Q2 / downside	-46.82 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2027q2_cfo, downside_2027q2_capex).
Company-owned life insurance purchases downside_2027q2_life_insurance	2027Q2 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2027q2_award_cash	2027Q2 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2027q2_lease_principal	2027Q2 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2027q2_other_cash	2027Q2 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2027q2_life_insurance, downside_2027q2_award_cash, downside_2027q2_lease_principal).
Cash after other cash uses downside_2027q2_cash_after_claims	2027Q2 / downside	-53.67 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2027q2_fcf, downside_2027q2_other_cash).
Prior H2 idose downside_2027q3_idose_h2	2027Q3 / downside	134.34 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_idose, downside_2026q4_idose).
Half-year annualization downside_2027q3_idose_annualize	2027Q3 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q3_idose_growth	2027Q3 / downside	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q3_idose_season	2027Q3 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2027q3_idose	2027Q3 / downside	74.16 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q3_idose_h2, downside_2027q3_idose_annualize, downside_2027q3_idose_growth, downside_2027q3_idose_season).
Prior H2 us_other downside_2027q3_us_other_h2	2027Q3 / downside	75.71 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_us_other, downside_2026q4_us_other).
Half-year annualization downside_2027q3_us_other_annualize	2027Q3 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q3_us_other_growth	2027Q3 / downside	100.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q3_us_other_season	2027Q3 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue downside_2027q3_us_other	2027Q3 / downside	36.34 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q3_us_other_h2, downside_2027q3_us_other_annualize, downside_2027q3_us_other_growth, downside_2027q3_us_other_season).
Prior H2 international downside_2027q3_international_h2	2027Q3 / downside	63.12 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_international, downside_2026q4_international).
Half-year annualization downside_2027q3_international_annualize	2027Q3 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q3_international_growth	2027Q3 / downside	105.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q3_international_season	2027Q3 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2027q3_international	2027Q3 / downside	31.81 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q3_international_h2, downside_2027q3_international_annualize, downside_2027q3_international_growth, downside_2027q3_international_season).
Prior H2 epioxa downside_2027q3_epioxa_h2	2027Q3 / downside	25.38 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_epioxa, downside_2026q4_epioxa).
Half-year annualization downside_2027q3_epioxa_annualize	2027Q3 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q3_epioxa_growth	2027Q3 / downside	145.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q3_epioxa_season	2027Q3 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue downside_2027q3_epioxa	2027Q3 / downside	17.67 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q3_epioxa_h2, downside_2027q3_epioxa_annualize, downside_2027q3_epioxa_growth, downside_2027q3_epioxa_season).
Prior H2 corneal_other downside_2027q3_corneal_other_h2	2027Q3 / downside	13.86 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_corneal_other, downside_2026q4_corneal_other).
Half-year annualization downside_2027q3_corneal_other_annualize	2027Q3 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q3_corneal_other_growth	2027Q3 / downside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q3_corneal_other_season	2027Q3 / downside	24.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue downside_2027q3_corneal_other	2027Q3 / downside	5.99 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q3_corneal_other_h2, downside_2027q3_corneal_other_annualize, downside_2027q3_corneal_other_growth, downside_2027q3_corneal_other_season).
Revenue downside_2027q3_revenue	2027Q3 / downside	165.97 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(downside_2027q3_idose, downside_2027q3_us_other, downside_2027q3_international, downside_2027q3_epioxa, downside_2027q3_corneal_other).
Non-GAAP gross margin downside_2027q3_ng_gm	2027Q3 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2027q3_ng_gross_profit	2027Q3 / downside	136.09 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2027q3_revenue, downside_2027q3_ng_gm).
Acquired amortization in COGS downside_2027q3_acquired_amort	2027Q3 / downside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2027q3_gross_profit	2027Q3 / downside	131.89 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2027q3_ng_gross_profit, downside_2027q3_acquired_amort).
SG&A excluding stock compensation downside_2027q3_sg_cash	2027Q3 / downside	97.44 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2027q3_sg_sbc	2027Q3 / downside	15.40 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2027q3_sg	2027Q3 / downside	112.84 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2027q3_sg_cash, downside_2027q3_sg_sbc).
R&D including equity compensation downside_2027q3_rd	2027Q3 / downside	59.36 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2027q3_ipr	2027Q3 / downside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2027q3_ng_opex	2027Q3 / downside	172.20 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2027q3_sg, downside_2027q3_rd, downside_2027q3_ipr).
Non-GAAP operating income downside_2027q3_non_gaap_op	2027Q3 / downside	-36.11 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2027q3_ng_gross_profit, downside_2027q3_ng_opex).
Specific cash legal and integration costs downside_2027q3_special	2027Q3 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2027q3_op_before_special	2027Q3 / downside	-40.31 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2027q3_non_gaap_op, downside_2027q3_acquired_amort).
GAAP operating income downside_2027q3_operating_income	2027Q3 / downside	-42.31 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2027q3_op_before_special, downside_2027q3_special).
R&D and COGS equity compensation downside_2027q3_other_sbc	2027Q3 / downside	7.30 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2027q3_sbc	2027Q3 / downside	22.70 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2027q3_sg_sbc, downside_2027q3_other_sbc).
Other depreciation downside_2027q3_depreciation	2027Q3 / downside	4.00 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2027q3_net_interest	2027Q3 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2027q3_cash_before_uses	2027Q3 / downside	-10.91 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2027q3_operating_income, downside_2027q3_sbc, downside_2027q3_acquired_amort, downside_2027q3_depreciation, downside_2027q3_net_interest).
Net working-capital use / sales downside_2027q3_wc_ratio	2027Q3 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2027q3_wc	2027Q3 / downside	24.89 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2027q3_revenue, downside_2027q3_wc_ratio).
Cash taxes downside_2027q3_tax	2027Q3 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2027q3_operating_cash_uses	2027Q3 / downside	25.59 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2027q3_wc, downside_2027q3_tax).
Operating cash flow downside_2027q3_cfo	2027Q3 / downside	-36.50 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2027q3_cash_before_uses, downside_2027q3_operating_cash_uses).
PP&E including construction spending downside_2027q3_capex	2027Q3 / downside	19.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2027q3_fcf	2027Q3 / downside	-55.50 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2027q3_cfo, downside_2027q3_capex).
Company-owned life insurance purchases downside_2027q3_life_insurance	2027Q3 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2027q3_award_cash	2027Q3 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2027q3_lease_principal	2027Q3 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2027q3_other_cash	2027Q3 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2027q3_life_insurance, downside_2027q3_award_cash, downside_2027q3_lease_principal).
Cash after other cash uses downside_2027q3_cash_after_claims	2027Q3 / downside	-62.35 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2027q3_fcf, downside_2027q3_other_cash).
Prior H2 idose downside_2027q4_idose_h2	2027Q4 / downside	134.34 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_idose, downside_2026q4_idose).
Half-year annualization downside_2027q4_idose_annualize	2027Q4 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q4_idose_growth	2027Q4 / downside	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q4_idose_season	2027Q4 / downside	28.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue downside_2027q4_idose	2027Q4 / downside	86.52 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q4_idose_h2, downside_2027q4_idose_annualize, downside_2027q4_idose_growth, downside_2027q4_idose_season).
Prior H2 us_other downside_2027q4_us_other_h2	2027Q4 / downside	75.71 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_us_other, downside_2026q4_us_other).
Half-year annualization downside_2027q4_us_other_annualize	2027Q4 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q4_us_other_growth	2027Q4 / downside	100.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q4_us_other_season	2027Q4 / downside	28.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue downside_2027q4_us_other	2027Q4 / downside	42.40 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q4_us_other_h2, downside_2027q4_us_other_annualize, downside_2027q4_us_other_growth, downside_2027q4_us_other_season).
Prior H2 international downside_2027q4_international_h2	2027Q4 / downside	63.12 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_international, downside_2026q4_international).
Half-year annualization downside_2027q4_international_annualize	2027Q4 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q4_international_growth	2027Q4 / downside	105.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q4_international_season	2027Q4 / downside	28.0% ratio	assumption: Desk assumption, not company guidance.
international revenue downside_2027q4_international	2027Q4 / downside	37.12 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q4_international_h2, downside_2027q4_international_annualize, downside_2027q4_international_growth, downside_2027q4_international_season).
Prior H2 epioxa downside_2027q4_epioxa_h2	2027Q4 / downside	25.38 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_epioxa, downside_2026q4_epioxa).
Half-year annualization downside_2027q4_epioxa_annualize	2027Q4 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q4_epioxa_growth	2027Q4 / downside	145.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q4_epioxa_season	2027Q4 / downside	28.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue downside_2027q4_epioxa	2027Q4 / downside	20.61 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q4_epioxa_h2, downside_2027q4_epioxa_annualize, downside_2027q4_epioxa_growth, downside_2027q4_epioxa_season).
Prior H2 corneal_other downside_2027q4_corneal_other_h2	2027Q4 / downside	13.86 USD_millions	derived: Known model reference, not reported product history. Formula: sum(downside_2026q3_corneal_other, downside_2026q4_corneal_other).
Half-year annualization downside_2027q4_corneal_other_annualize	2027Q4 / downside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion downside_2027q4_corneal_other_growth	2027Q4 / downside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share downside_2027q4_corneal_other_season	2027Q4 / downside	28.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue downside_2027q4_corneal_other	2027Q4 / downside	6.98 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(downside_2027q4_corneal_other_h2, downside_2027q4_corneal_other_annualize, downside_2027q4_corneal_other_growth, downside_2027q4_corneal_other_season).
Revenue downside_2027q4_revenue	2027Q4 / downside	193.63 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(downside_2027q4_idose, downside_2027q4_us_other, downside_2027q4_international, downside_2027q4_epioxa, downside_2027q4_corneal_other).
Non-GAAP gross margin downside_2027q4_ng_gm	2027Q4 / downside	82.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit downside_2027q4_ng_gross_profit	2027Q4 / downside	158.77 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(downside_2027q4_revenue, downside_2027q4_ng_gm).
Acquired amortization in COGS downside_2027q4_acquired_amort	2027Q4 / downside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit downside_2027q4_gross_profit	2027Q4 / downside	154.57 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(downside_2027q4_ng_gross_profit, downside_2027q4_acquired_amort).
SG&A excluding stock compensation downside_2027q4_sg_cash	2027Q4 / downside	100.80 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation downside_2027q4_sg_sbc	2027Q4 / downside	16.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A downside_2027q4_sg	2027Q4 / downside	116.80 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(downside_2027q4_sg_cash, downside_2027q4_sg_sbc).
R&D including equity compensation downside_2027q4_rd	2027Q4 / downside	60.95 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense downside_2027q4_ipr	2027Q4 / downside	2.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs downside_2027q4_ng_opex	2027Q4 / downside	179.75 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(downside_2027q4_sg, downside_2027q4_rd, downside_2027q4_ipr).
Non-GAAP operating income downside_2027q4_non_gaap_op	2027Q4 / downside	-20.98 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(downside_2027q4_ng_gross_profit, downside_2027q4_ng_opex).
Specific cash legal and integration costs downside_2027q4_special	2027Q4 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization downside_2027q4_op_before_special	2027Q4 / downside	-25.18 USD_millions	derived: Same amortization as gross profit. Formula: subtract(downside_2027q4_non_gaap_op, downside_2027q4_acquired_amort).
GAAP operating income downside_2027q4_operating_income	2027Q4 / downside	-27.18 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(downside_2027q4_op_before_special, downside_2027q4_special).
R&D and COGS equity compensation downside_2027q4_other_sbc	2027Q4 / downside	7.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation downside_2027q4_sbc	2027Q4 / downside	23.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(downside_2027q4_sg_sbc, downside_2027q4_other_sbc).
Other depreciation downside_2027q4_depreciation	2027Q4 / downside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest downside_2027q4_net_interest	2027Q4 / downside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes downside_2027q4_cash_before_uses	2027Q4 / downside	5.22 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(downside_2027q4_operating_income, downside_2027q4_sbc, downside_2027q4_acquired_amort, downside_2027q4_depreciation, downside_2027q4_net_interest).
Net working-capital use / sales downside_2027q4_wc_ratio	2027Q4 / downside	15.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use downside_2027q4_wc	2027Q4 / downside	29.04 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(downside_2027q4_revenue, downside_2027q4_wc_ratio).
Cash taxes downside_2027q4_tax	2027Q4 / downside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes downside_2027q4_operating_cash_uses	2027Q4 / downside	29.74 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(downside_2027q4_wc, downside_2027q4_tax).
Operating cash flow downside_2027q4_cfo	2027Q4 / downside	-24.52 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(downside_2027q4_cash_before_uses, downside_2027q4_operating_cash_uses).
PP&E including construction spending downside_2027q4_capex	2027Q4 / downside	20.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex downside_2027q4_fcf	2027Q4 / downside	-44.52 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(downside_2027q4_cfo, downside_2027q4_capex).
Company-owned life insurance purchases downside_2027q4_life_insurance	2027Q4 / downside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding downside_2027q4_award_cash	2027Q4 / downside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal downside_2027q4_lease_principal	2027Q4 / downside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses downside_2027q4_other_cash	2027Q4 / downside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(downside_2027q4_life_insurance, downside_2027q4_award_cash, downside_2027q4_lease_principal).
Cash after other cash uses downside_2027q4_cash_after_claims	2027Q4 / downside	-51.37 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(downside_2027q4_fcf, downside_2027q4_other_cash).
Revenue ($M) downside_fy2026_revenue	FY2026 / downside	648.60 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_revenue, downside_2026q3_revenue, downside_2026q4_revenue).
GAAP gross profit proxy ($M) downside_fy2026_gross_profit	FY2026 / downside	514.41 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_gross_profit, downside_2026q3_gross_profit, downside_2026q4_gross_profit).
Non-GAAP operating income proxy ($M) downside_fy2026_non_gaap_op	FY2026 / downside	-68.94 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_non_gaap_op, downside_2026q3_non_gaap_op, downside_2026q4_non_gaap_op).
GAAP operating income proxy ($M) downside_fy2026_operating_income	FY2026 / downside	-105.59 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_operating_income, downside_2026q3_operating_income, downside_2026q4_operating_income).
Operating cash flow ($M) downside_fy2026_cfo	FY2026 / downside	-56.43 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cfo, downside_2026q3_cfo, downside_2026q4_cfo).
PP&E and construction cash ($M) downside_fy2026_capex	FY2026 / downside	29.70 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_capex, downside_2026q3_capex, downside_2026q4_capex).
CFO less capex ($M) downside_fy2026_fcf	FY2026 / downside	-86.13 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_fcf, downside_2026q3_fcf, downside_2026q4_fcf).
Cash after capex and other cash uses ($M) downside_fy2026_cash_after_claims	FY2026 / downside	-112.77 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cash_after_claims, downside_2026q3_cash_after_claims, downside_2026q4_cash_after_claims).
Revenue ($M) downside_fy2027_revenue	FY2027 / downside	691.52 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_revenue, downside_2027q2_revenue, downside_2027q3_revenue, downside_2027q4_revenue).
GAAP gross profit proxy ($M) downside_fy2027_gross_profit	FY2027 / downside	550.25 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_gross_profit, downside_2027q2_gross_profit, downside_2027q3_gross_profit, downside_2027q4_gross_profit).
Non-GAAP operating income proxy ($M) downside_fy2027_non_gaap_op	FY2027 / downside	-114.15 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_non_gaap_op, downside_2027q2_non_gaap_op, downside_2027q3_non_gaap_op, downside_2027q4_non_gaap_op).
GAAP operating income proxy ($M) downside_fy2027_operating_income	FY2027 / downside	-138.95 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_operating_income, downside_2027q2_operating_income, downside_2027q3_operating_income, downside_2027q4_operating_income).
Operating cash flow ($M) downside_fy2027_cfo	FY2027 / downside	-121.88 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_cfo, downside_2027q2_cfo, downside_2027q3_cfo, downside_2027q4_cfo).
PP&E and construction cash ($M) downside_fy2027_capex	FY2027 / downside	72.00 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_capex, downside_2027q2_capex, downside_2027q3_capex, downside_2027q4_capex).
CFO less capex ($M) downside_fy2027_fcf	FY2027 / downside	-193.88 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_fcf, downside_2027q2_fcf, downside_2027q3_fcf, downside_2027q4_fcf).
Cash after capex and other cash uses ($M) downside_fy2027_cash_after_claims	FY2027 / downside	-221.28 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(downside_2027q1_cash_after_claims, downside_2027q2_cash_after_claims, downside_2027q3_cash_after_claims, downside_2027q4_cash_after_claims).
Annual sales / guidance midpoint base_delivery	FY2026 / base	100.0% ratio	assumption: Desk delivery and market-access sensitivity.
Annual revenue scenario base_target	FY2026 / base	690.00 USD_millions	derived: Nominal revenue including FX. Formula: multiply(annual_guide, base_delivery).
Remaining H2 revenue base_h2	H2 2026 / base	353.82 USD_millions	derived: Annual scenario less reported H1. Formula: subtract(base_target, h1_revenue).
Share of H2 sales base_2026q3_h2_weight	2026Q3 / base	47.0% ratio	assumption: Desk assumption, not company guidance.
Revenue base_2026q3_revenue	2026Q3 / base	166.29 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(base_h2, base_2026q3_h2_weight).
idose mix base_2026q3_idose_mix	2026Q3 / base	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2026q3_idose	2026Q3 / base	71.51 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q3_revenue, base_2026q3_idose_mix).
us_other mix base_2026q3_us_other_mix	2026Q3 / base	24.5% ratio	assumption: Desk assumption, not company guidance.
us other revenue base_2026q3_us_other	2026Q3 / base	40.74 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q3_revenue, base_2026q3_us_other_mix).
international mix base_2026q3_international_mix	2026Q3 / base	21.0% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2026q3_international	2026Q3 / base	34.92 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q3_revenue, base_2026q3_international_mix).
corneal mix base_2026q3_corneal_mix	2026Q3 / base	11.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue base_2026q3_corneal	2026Q3 / base	19.12 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q3_revenue, base_2026q3_corneal_mix).
Epioxa share of corneal base_2026q3_epioxa_mix	2026Q3 / base	55.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue base_2026q3_epioxa	2026Q3 / base	10.52 USD_millions	derived: Subset of corneal health. Formula: multiply(base_2026q3_corneal, base_2026q3_epioxa_mix).
Other corneal revenue base_2026q3_corneal_other	2026Q3 / base	8.61 USD_millions	derived: No Epioxa double counting. Formula: subtract(base_2026q3_corneal, base_2026q3_epioxa).
Non-GAAP gross margin base_2026q3_ng_gm	2026Q3 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2026q3_ng_gross_profit	2026Q3 / base	140.52 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2026q3_revenue, base_2026q3_ng_gm).
Acquired amortization in COGS base_2026q3_acquired_amort	2026Q3 / base	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2026q3_gross_profit	2026Q3 / base	135.22 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2026q3_ng_gross_profit, base_2026q3_acquired_amort).
SG&A excluding stock compensation base_2026q3_sg_cash	2026Q3 / base	80.00 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2026q3_sg_sbc	2026Q3 / base	13.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2026q3_sg	2026Q3 / base	93.00 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2026q3_sg_cash, base_2026q3_sg_sbc).
R&D including equity compensation base_2026q3_rd	2026Q3 / base	50.00 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2026q3_ipr	2026Q3 / base	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2026q3_ng_opex	2026Q3 / base	143.00 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2026q3_sg, base_2026q3_rd, base_2026q3_ipr).
Non-GAAP operating income base_2026q3_non_gaap_op	2026Q3 / base	-2.48 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2026q3_ng_gross_profit, base_2026q3_ng_opex).
Specific cash legal and integration costs base_2026q3_special	2026Q3 / base	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2026q3_op_before_special	2026Q3 / base	-7.78 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2026q3_non_gaap_op, base_2026q3_acquired_amort).
GAAP operating income base_2026q3_operating_income	2026Q3 / base	-11.28 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2026q3_op_before_special, base_2026q3_special).
R&D and COGS equity compensation base_2026q3_other_sbc	2026Q3 / base	6.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2026q3_sbc	2026Q3 / base	19.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2026q3_sg_sbc, base_2026q3_other_sbc).
Other depreciation base_2026q3_depreciation	2026Q3 / base	3.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2026q3_net_interest	2026Q3 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2026q3_cash_before_uses	2026Q3 / base	17.22 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2026q3_operating_income, base_2026q3_sbc, base_2026q3_acquired_amort, base_2026q3_depreciation, base_2026q3_net_interest).
Net working-capital use / sales base_2026q3_wc_ratio	2026Q3 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2026q3_wc	2026Q3 / base	14.97 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2026q3_revenue, base_2026q3_wc_ratio).
Cash taxes base_2026q3_tax	2026Q3 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2026q3_operating_cash_uses	2026Q3 / base	15.67 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2026q3_wc, base_2026q3_tax).
Operating cash flow base_2026q3_cfo	2026Q3 / base	1.55 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2026q3_cash_before_uses, base_2026q3_operating_cash_uses).
PP&E including construction spending base_2026q3_capex	2026Q3 / base	8.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2026q3_fcf	2026Q3 / base	-6.45 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2026q3_cfo, base_2026q3_capex).
Company-owned life insurance purchases base_2026q3_life_insurance	2026Q3 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2026q3_award_cash	2026Q3 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2026q3_lease_principal	2026Q3 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2026q3_other_cash	2026Q3 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2026q3_life_insurance, base_2026q3_award_cash, base_2026q3_lease_principal).
Cash after other cash uses base_2026q3_cash_after_claims	2026Q3 / base	-13.30 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2026q3_fcf, base_2026q3_other_cash).
Share of H2 sales base_2026q4_h2_weight	2026Q4 / base	53.0% ratio	assumption: Desk assumption, not company guidance.
Revenue base_2026q4_revenue	2026Q4 / base	187.52 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(base_h2, base_2026q4_h2_weight).
idose mix base_2026q4_idose_mix	2026Q4 / base	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2026q4_idose	2026Q4 / base	80.64 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q4_revenue, base_2026q4_idose_mix).
us_other mix base_2026q4_us_other_mix	2026Q4 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
us other revenue base_2026q4_us_other	2026Q4 / base	45.01 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q4_revenue, base_2026q4_us_other_mix).
international mix base_2026q4_international_mix	2026Q4 / base	19.5% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2026q4_international	2026Q4 / base	36.57 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q4_revenue, base_2026q4_international_mix).
corneal mix base_2026q4_corneal_mix	2026Q4 / base	13.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue base_2026q4_corneal	2026Q4 / base	25.32 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(base_2026q4_revenue, base_2026q4_corneal_mix).
Epioxa share of corneal base_2026q4_epioxa_mix	2026Q4 / base	72.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue base_2026q4_epioxa	2026Q4 / base	18.23 USD_millions	derived: Subset of corneal health. Formula: multiply(base_2026q4_corneal, base_2026q4_epioxa_mix).
Other corneal revenue base_2026q4_corneal_other	2026Q4 / base	7.09 USD_millions	derived: No Epioxa double counting. Formula: subtract(base_2026q4_corneal, base_2026q4_epioxa).
Non-GAAP gross margin base_2026q4_ng_gm	2026Q4 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2026q4_ng_gross_profit	2026Q4 / base	158.46 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2026q4_revenue, base_2026q4_ng_gm).
Acquired amortization in COGS base_2026q4_acquired_amort	2026Q4 / base	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2026q4_gross_profit	2026Q4 / base	153.16 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2026q4_ng_gross_profit, base_2026q4_acquired_amort).
SG&A excluding stock compensation base_2026q4_sg_cash	2026Q4 / base	83.20 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2026q4_sg_sbc	2026Q4 / base	13.60 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2026q4_sg	2026Q4 / base	96.80 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2026q4_sg_cash, base_2026q4_sg_sbc).
R&D including equity compensation base_2026q4_rd	2026Q4 / base	51.50 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2026q4_ipr	2026Q4 / base	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2026q4_ng_opex	2026Q4 / base	149.80 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2026q4_sg, base_2026q4_rd, base_2026q4_ipr).
Non-GAAP operating income base_2026q4_non_gaap_op	2026Q4 / base	8.66 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2026q4_ng_gross_profit, base_2026q4_ng_opex).
Specific cash legal and integration costs base_2026q4_special	2026Q4 / base	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2026q4_op_before_special	2026Q4 / base	3.36 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2026q4_non_gaap_op, base_2026q4_acquired_amort).
GAAP operating income base_2026q4_operating_income	2026Q4 / base	-0.14 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2026q4_op_before_special, base_2026q4_special).
R&D and COGS equity compensation base_2026q4_other_sbc	2026Q4 / base	6.70 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2026q4_sbc	2026Q4 / base	20.30 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2026q4_sg_sbc, base_2026q4_other_sbc).
Other depreciation base_2026q4_depreciation	2026Q4 / base	3.40 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2026q4_net_interest	2026Q4 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2026q4_cash_before_uses	2026Q4 / base	29.36 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2026q4_operating_income, base_2026q4_sbc, base_2026q4_acquired_amort, base_2026q4_depreciation, base_2026q4_net_interest).
Net working-capital use / sales base_2026q4_wc_ratio	2026Q4 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2026q4_wc	2026Q4 / base	16.88 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2026q4_revenue, base_2026q4_wc_ratio).
Cash taxes base_2026q4_tax	2026Q4 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2026q4_operating_cash_uses	2026Q4 / base	17.58 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2026q4_wc, base_2026q4_tax).
Operating cash flow base_2026q4_cfo	2026Q4 / base	11.78 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2026q4_cash_before_uses, base_2026q4_operating_cash_uses).
PP&E including construction spending base_2026q4_capex	2026Q4 / base	11.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2026q4_fcf	2026Q4 / base	0.78 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2026q4_cfo, base_2026q4_capex).
Company-owned life insurance purchases base_2026q4_life_insurance	2026Q4 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2026q4_award_cash	2026Q4 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2026q4_lease_principal	2026Q4 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2026q4_other_cash	2026Q4 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2026q4_life_insurance, base_2026q4_award_cash, base_2026q4_lease_principal).
Cash after other cash uses base_2026q4_cash_after_claims	2026Q4 / base	-6.07 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2026q4_fcf, base_2026q4_other_cash).
Prior H2 idose base_2027q1_idose_h2	2027Q1 / base	152.14 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_idose, base_2026q4_idose).
Half-year annualization base_2027q1_idose_annualize	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q1_idose_growth	2027Q1 / base	140.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q1_idose_season	2027Q1 / base	23.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2027q1_idose	2027Q1 / base	97.98 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q1_idose_h2, base_2027q1_idose_annualize, base_2027q1_idose_growth, base_2027q1_idose_season).
Prior H2 us_other base_2027q1_us_other_h2	2027Q1 / base	85.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_us_other, base_2026q4_us_other).
Half-year annualization base_2027q1_us_other_annualize	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q1_us_other_growth	2027Q1 / base	103.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q1_us_other_season	2027Q1 / base	23.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue base_2027q1_us_other	2027Q1 / base	40.63 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q1_us_other_h2, base_2027q1_us_other_annualize, base_2027q1_us_other_growth, base_2027q1_us_other_season).
Prior H2 international base_2027q1_international_h2	2027Q1 / base	71.49 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_international, base_2026q4_international).
Half-year annualization base_2027q1_international_annualize	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q1_international_growth	2027Q1 / base	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q1_international_season	2027Q1 / base	23.0% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2027q1_international	2027Q1 / base	37.82 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q1_international_h2, base_2027q1_international_annualize, base_2027q1_international_growth, base_2027q1_international_season).
Prior H2 epioxa base_2027q1_epioxa_h2	2027Q1 / base	28.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_epioxa, base_2026q4_epioxa).
Half-year annualization base_2027q1_epioxa_annualize	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q1_epioxa_growth	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q1_epioxa_season	2027Q1 / base	23.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue base_2027q1_epioxa	2027Q1 / base	26.45 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q1_epioxa_h2, base_2027q1_epioxa_annualize, base_2027q1_epioxa_growth, base_2027q1_epioxa_season).
Prior H2 corneal_other base_2027q1_corneal_other_h2	2027Q1 / base	15.69 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_corneal_other, base_2026q4_corneal_other).
Half-year annualization base_2027q1_corneal_other_annualize	2027Q1 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q1_corneal_other_growth	2027Q1 / base	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q1_corneal_other_season	2027Q1 / base	23.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue base_2027q1_corneal_other	2027Q1 / base	6.50 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q1_corneal_other_h2, base_2027q1_corneal_other_annualize, base_2027q1_corneal_other_growth, base_2027q1_corneal_other_season).
Revenue base_2027q1_revenue	2027Q1 / base	209.37 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(base_2027q1_idose, base_2027q1_us_other, base_2027q1_international, base_2027q1_epioxa, base_2027q1_corneal_other).
Non-GAAP gross margin base_2027q1_ng_gm	2027Q1 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2027q1_ng_gross_profit	2027Q1 / base	176.92 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2027q1_revenue, base_2027q1_ng_gm).
Acquired amortization in COGS base_2027q1_acquired_amort	2027Q1 / base	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2027q1_gross_profit	2027Q1 / base	172.72 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2027q1_ng_gross_profit, base_2027q1_acquired_amort).
SG&A excluding stock compensation base_2027q1_sg_cash	2027Q1 / base	86.40 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2027q1_sg_sbc	2027Q1 / base	14.20 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2027q1_sg	2027Q1 / base	100.60 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2027q1_sg_cash, base_2027q1_sg_sbc).
R&D including equity compensation base_2027q1_rd	2027Q1 / base	53.00 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2027q1_ipr	2027Q1 / base	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2027q1_ng_opex	2027Q1 / base	153.60 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2027q1_sg, base_2027q1_rd, base_2027q1_ipr).
Non-GAAP operating income base_2027q1_non_gaap_op	2027Q1 / base	23.32 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2027q1_ng_gross_profit, base_2027q1_ng_opex).
Specific cash legal and integration costs base_2027q1_special	2027Q1 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2027q1_op_before_special	2027Q1 / base	19.12 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2027q1_non_gaap_op, base_2027q1_acquired_amort).
GAAP operating income base_2027q1_operating_income	2027Q1 / base	17.12 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2027q1_op_before_special, base_2027q1_special).
R&D and COGS equity compensation base_2027q1_other_sbc	2027Q1 / base	6.90 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2027q1_sbc	2027Q1 / base	21.10 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2027q1_sg_sbc, base_2027q1_other_sbc).
Other depreciation base_2027q1_depreciation	2027Q1 / base	3.60 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2027q1_net_interest	2027Q1 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2027q1_cash_before_uses	2027Q1 / base	46.52 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2027q1_operating_income, base_2027q1_sbc, base_2027q1_acquired_amort, base_2027q1_depreciation, base_2027q1_net_interest).
Net working-capital use / sales base_2027q1_wc_ratio	2027Q1 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2027q1_wc	2027Q1 / base	18.84 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2027q1_revenue, base_2027q1_wc_ratio).
Cash taxes base_2027q1_tax	2027Q1 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2027q1_operating_cash_uses	2027Q1 / base	19.54 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2027q1_wc, base_2027q1_tax).
Operating cash flow base_2027q1_cfo	2027Q1 / base	26.97 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2027q1_cash_before_uses, base_2027q1_operating_cash_uses).
PP&E including construction spending base_2027q1_capex	2027Q1 / base	13.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2027q1_fcf	2027Q1 / base	13.97 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2027q1_cfo, base_2027q1_capex).
Company-owned life insurance purchases base_2027q1_life_insurance	2027Q1 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2027q1_award_cash	2027Q1 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2027q1_lease_principal	2027Q1 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2027q1_other_cash	2027Q1 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2027q1_life_insurance, base_2027q1_award_cash, base_2027q1_lease_principal).
Cash after other cash uses base_2027q1_cash_after_claims	2027Q1 / base	7.12 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2027q1_fcf, base_2027q1_other_cash).
Prior H2 idose base_2027q2_idose_h2	2027Q2 / base	152.14 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_idose, base_2026q4_idose).
Half-year annualization base_2027q2_idose_annualize	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q2_idose_growth	2027Q2 / base	140.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q2_idose_season	2027Q2 / base	25.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2027q2_idose	2027Q2 / base	106.50 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q2_idose_h2, base_2027q2_idose_annualize, base_2027q2_idose_growth, base_2027q2_idose_season).
Prior H2 us_other base_2027q2_us_other_h2	2027Q2 / base	85.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_us_other, base_2026q4_us_other).
Half-year annualization base_2027q2_us_other_annualize	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q2_us_other_growth	2027Q2 / base	103.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q2_us_other_season	2027Q2 / base	25.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue base_2027q2_us_other	2027Q2 / base	44.16 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q2_us_other_h2, base_2027q2_us_other_annualize, base_2027q2_us_other_growth, base_2027q2_us_other_season).
Prior H2 international base_2027q2_international_h2	2027Q2 / base	71.49 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_international, base_2026q4_international).
Half-year annualization base_2027q2_international_annualize	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q2_international_growth	2027Q2 / base	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q2_international_season	2027Q2 / base	25.0% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2027q2_international	2027Q2 / base	41.11 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q2_international_h2, base_2027q2_international_annualize, base_2027q2_international_growth, base_2027q2_international_season).
Prior H2 epioxa base_2027q2_epioxa_h2	2027Q2 / base	28.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_epioxa, base_2026q4_epioxa).
Half-year annualization base_2027q2_epioxa_annualize	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q2_epioxa_growth	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q2_epioxa_season	2027Q2 / base	25.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue base_2027q2_epioxa	2027Q2 / base	28.75 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q2_epioxa_h2, base_2027q2_epioxa_annualize, base_2027q2_epioxa_growth, base_2027q2_epioxa_season).
Prior H2 corneal_other base_2027q2_corneal_other_h2	2027Q2 / base	15.69 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_corneal_other, base_2026q4_corneal_other).
Half-year annualization base_2027q2_corneal_other_annualize	2027Q2 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q2_corneal_other_growth	2027Q2 / base	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q2_corneal_other_season	2027Q2 / base	25.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue base_2027q2_corneal_other	2027Q2 / base	7.06 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q2_corneal_other_h2, base_2027q2_corneal_other_annualize, base_2027q2_corneal_other_growth, base_2027q2_corneal_other_season).
Revenue base_2027q2_revenue	2027Q2 / base	227.57 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(base_2027q2_idose, base_2027q2_us_other, base_2027q2_international, base_2027q2_epioxa, base_2027q2_corneal_other).
Non-GAAP gross margin base_2027q2_ng_gm	2027Q2 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2027q2_ng_gross_profit	2027Q2 / base	192.30 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2027q2_revenue, base_2027q2_ng_gm).
Acquired amortization in COGS base_2027q2_acquired_amort	2027Q2 / base	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2027q2_gross_profit	2027Q2 / base	188.10 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2027q2_ng_gross_profit, base_2027q2_acquired_amort).
SG&A excluding stock compensation base_2027q2_sg_cash	2027Q2 / base	89.60 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2027q2_sg_sbc	2027Q2 / base	14.80 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2027q2_sg	2027Q2 / base	104.40 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2027q2_sg_cash, base_2027q2_sg_sbc).
R&D including equity compensation base_2027q2_rd	2027Q2 / base	54.50 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2027q2_ipr	2027Q2 / base	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2027q2_ng_opex	2027Q2 / base	160.40 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2027q2_sg, base_2027q2_rd, base_2027q2_ipr).
Non-GAAP operating income base_2027q2_non_gaap_op	2027Q2 / base	31.90 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2027q2_ng_gross_profit, base_2027q2_ng_opex).
Specific cash legal and integration costs base_2027q2_special	2027Q2 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2027q2_op_before_special	2027Q2 / base	27.70 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2027q2_non_gaap_op, base_2027q2_acquired_amort).
GAAP operating income base_2027q2_operating_income	2027Q2 / base	25.70 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2027q2_op_before_special, base_2027q2_special).
R&D and COGS equity compensation base_2027q2_other_sbc	2027Q2 / base	7.10 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2027q2_sbc	2027Q2 / base	21.90 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2027q2_sg_sbc, base_2027q2_other_sbc).
Other depreciation base_2027q2_depreciation	2027Q2 / base	3.80 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2027q2_net_interest	2027Q2 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2027q2_cash_before_uses	2027Q2 / base	56.10 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2027q2_operating_income, base_2027q2_sbc, base_2027q2_acquired_amort, base_2027q2_depreciation, base_2027q2_net_interest).
Net working-capital use / sales base_2027q2_wc_ratio	2027Q2 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2027q2_wc	2027Q2 / base	20.48 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2027q2_revenue, base_2027q2_wc_ratio).
Cash taxes base_2027q2_tax	2027Q2 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2027q2_operating_cash_uses	2027Q2 / base	21.18 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2027q2_wc, base_2027q2_tax).
Operating cash flow base_2027q2_cfo	2027Q2 / base	34.92 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2027q2_cash_before_uses, base_2027q2_operating_cash_uses).
PP&E including construction spending base_2027q2_capex	2027Q2 / base	15.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2027q2_fcf	2027Q2 / base	19.92 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2027q2_cfo, base_2027q2_capex).
Company-owned life insurance purchases base_2027q2_life_insurance	2027Q2 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2027q2_award_cash	2027Q2 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2027q2_lease_principal	2027Q2 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2027q2_other_cash	2027Q2 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2027q2_life_insurance, base_2027q2_award_cash, base_2027q2_lease_principal).
Cash after other cash uses base_2027q2_cash_after_claims	2027Q2 / base	13.07 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2027q2_fcf, base_2027q2_other_cash).
Prior H2 idose base_2027q3_idose_h2	2027Q3 / base	152.14 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_idose, base_2026q4_idose).
Half-year annualization base_2027q3_idose_annualize	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q3_idose_growth	2027Q3 / base	140.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q3_idose_season	2027Q3 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2027q3_idose	2027Q3 / base	102.24 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q3_idose_h2, base_2027q3_idose_annualize, base_2027q3_idose_growth, base_2027q3_idose_season).
Prior H2 us_other base_2027q3_us_other_h2	2027Q3 / base	85.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_us_other, base_2026q4_us_other).
Half-year annualization base_2027q3_us_other_annualize	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q3_us_other_growth	2027Q3 / base	103.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q3_us_other_season	2027Q3 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue base_2027q3_us_other	2027Q3 / base	42.39 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q3_us_other_h2, base_2027q3_us_other_annualize, base_2027q3_us_other_growth, base_2027q3_us_other_season).
Prior H2 international base_2027q3_international_h2	2027Q3 / base	71.49 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_international, base_2026q4_international).
Half-year annualization base_2027q3_international_annualize	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q3_international_growth	2027Q3 / base	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q3_international_season	2027Q3 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2027q3_international	2027Q3 / base	39.46 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q3_international_h2, base_2027q3_international_annualize, base_2027q3_international_growth, base_2027q3_international_season).
Prior H2 epioxa base_2027q3_epioxa_h2	2027Q3 / base	28.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_epioxa, base_2026q4_epioxa).
Half-year annualization base_2027q3_epioxa_annualize	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q3_epioxa_growth	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q3_epioxa_season	2027Q3 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue base_2027q3_epioxa	2027Q3 / base	27.60 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q3_epioxa_h2, base_2027q3_epioxa_annualize, base_2027q3_epioxa_growth, base_2027q3_epioxa_season).
Prior H2 corneal_other base_2027q3_corneal_other_h2	2027Q3 / base	15.69 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_corneal_other, base_2026q4_corneal_other).
Half-year annualization base_2027q3_corneal_other_annualize	2027Q3 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q3_corneal_other_growth	2027Q3 / base	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q3_corneal_other_season	2027Q3 / base	24.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue base_2027q3_corneal_other	2027Q3 / base	6.78 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q3_corneal_other_h2, base_2027q3_corneal_other_annualize, base_2027q3_corneal_other_growth, base_2027q3_corneal_other_season).
Revenue base_2027q3_revenue	2027Q3 / base	218.47 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(base_2027q3_idose, base_2027q3_us_other, base_2027q3_international, base_2027q3_epioxa, base_2027q3_corneal_other).
Non-GAAP gross margin base_2027q3_ng_gm	2027Q3 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2027q3_ng_gross_profit	2027Q3 / base	184.61 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2027q3_revenue, base_2027q3_ng_gm).
Acquired amortization in COGS base_2027q3_acquired_amort	2027Q3 / base	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2027q3_gross_profit	2027Q3 / base	180.41 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2027q3_ng_gross_profit, base_2027q3_acquired_amort).
SG&A excluding stock compensation base_2027q3_sg_cash	2027Q3 / base	92.80 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2027q3_sg_sbc	2027Q3 / base	15.40 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2027q3_sg	2027Q3 / base	108.20 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2027q3_sg_cash, base_2027q3_sg_sbc).
R&D including equity compensation base_2027q3_rd	2027Q3 / base	56.00 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2027q3_ipr	2027Q3 / base	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2027q3_ng_opex	2027Q3 / base	164.20 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2027q3_sg, base_2027q3_rd, base_2027q3_ipr).
Non-GAAP operating income base_2027q3_non_gaap_op	2027Q3 / base	20.41 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2027q3_ng_gross_profit, base_2027q3_ng_opex).
Specific cash legal and integration costs base_2027q3_special	2027Q3 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2027q3_op_before_special	2027Q3 / base	16.21 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2027q3_non_gaap_op, base_2027q3_acquired_amort).
GAAP operating income base_2027q3_operating_income	2027Q3 / base	14.21 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2027q3_op_before_special, base_2027q3_special).
R&D and COGS equity compensation base_2027q3_other_sbc	2027Q3 / base	7.30 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2027q3_sbc	2027Q3 / base	22.70 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2027q3_sg_sbc, base_2027q3_other_sbc).
Other depreciation base_2027q3_depreciation	2027Q3 / base	4.00 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2027q3_net_interest	2027Q3 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2027q3_cash_before_uses	2027Q3 / base	45.61 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2027q3_operating_income, base_2027q3_sbc, base_2027q3_acquired_amort, base_2027q3_depreciation, base_2027q3_net_interest).
Net working-capital use / sales base_2027q3_wc_ratio	2027Q3 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2027q3_wc	2027Q3 / base	19.66 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2027q3_revenue, base_2027q3_wc_ratio).
Cash taxes base_2027q3_tax	2027Q3 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2027q3_operating_cash_uses	2027Q3 / base	20.36 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2027q3_wc, base_2027q3_tax).
Operating cash flow base_2027q3_cfo	2027Q3 / base	25.25 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2027q3_cash_before_uses, base_2027q3_operating_cash_uses).
PP&E including construction spending base_2027q3_capex	2027Q3 / base	16.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2027q3_fcf	2027Q3 / base	9.25 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2027q3_cfo, base_2027q3_capex).
Company-owned life insurance purchases base_2027q3_life_insurance	2027Q3 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2027q3_award_cash	2027Q3 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2027q3_lease_principal	2027Q3 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2027q3_other_cash	2027Q3 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2027q3_life_insurance, base_2027q3_award_cash, base_2027q3_lease_principal).
Cash after other cash uses base_2027q3_cash_after_claims	2027Q3 / base	2.40 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2027q3_fcf, base_2027q3_other_cash).
Prior H2 idose base_2027q4_idose_h2	2027Q4 / base	152.14 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_idose, base_2026q4_idose).
Half-year annualization base_2027q4_idose_annualize	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q4_idose_growth	2027Q4 / base	140.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q4_idose_season	2027Q4 / base	28.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue base_2027q4_idose	2027Q4 / base	119.28 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q4_idose_h2, base_2027q4_idose_annualize, base_2027q4_idose_growth, base_2027q4_idose_season).
Prior H2 us_other base_2027q4_us_other_h2	2027Q4 / base	85.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_us_other, base_2026q4_us_other).
Half-year annualization base_2027q4_us_other_annualize	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q4_us_other_growth	2027Q4 / base	103.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q4_us_other_season	2027Q4 / base	28.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue base_2027q4_us_other	2027Q4 / base	49.46 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q4_us_other_h2, base_2027q4_us_other_annualize, base_2027q4_us_other_growth, base_2027q4_us_other_season).
Prior H2 international base_2027q4_international_h2	2027Q4 / base	71.49 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_international, base_2026q4_international).
Half-year annualization base_2027q4_international_annualize	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q4_international_growth	2027Q4 / base	115.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q4_international_season	2027Q4 / base	28.0% ratio	assumption: Desk assumption, not company guidance.
international revenue base_2027q4_international	2027Q4 / base	46.04 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q4_international_h2, base_2027q4_international_annualize, base_2027q4_international_growth, base_2027q4_international_season).
Prior H2 epioxa base_2027q4_epioxa_h2	2027Q4 / base	28.75 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_epioxa, base_2026q4_epioxa).
Half-year annualization base_2027q4_epioxa_annualize	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q4_epioxa_growth	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q4_epioxa_season	2027Q4 / base	28.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue base_2027q4_epioxa	2027Q4 / base	32.19 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q4_epioxa_h2, base_2027q4_epioxa_annualize, base_2027q4_epioxa_growth, base_2027q4_epioxa_season).
Prior H2 corneal_other base_2027q4_corneal_other_h2	2027Q4 / base	15.69 USD_millions	derived: Known model reference, not reported product history. Formula: sum(base_2026q3_corneal_other, base_2026q4_corneal_other).
Half-year annualization base_2027q4_corneal_other_annualize	2027Q4 / base	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion base_2027q4_corneal_other_growth	2027Q4 / base	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share base_2027q4_corneal_other_season	2027Q4 / base	28.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue base_2027q4_corneal_other	2027Q4 / base	7.91 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(base_2027q4_corneal_other_h2, base_2027q4_corneal_other_annualize, base_2027q4_corneal_other_growth, base_2027q4_corneal_other_season).
Revenue base_2027q4_revenue	2027Q4 / base	254.88 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(base_2027q4_idose, base_2027q4_us_other, base_2027q4_international, base_2027q4_epioxa, base_2027q4_corneal_other).
Non-GAAP gross margin base_2027q4_ng_gm	2027Q4 / base	84.5% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit base_2027q4_ng_gross_profit	2027Q4 / base	215.38 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(base_2027q4_revenue, base_2027q4_ng_gm).
Acquired amortization in COGS base_2027q4_acquired_amort	2027Q4 / base	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit base_2027q4_gross_profit	2027Q4 / base	211.18 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(base_2027q4_ng_gross_profit, base_2027q4_acquired_amort).
SG&A excluding stock compensation base_2027q4_sg_cash	2027Q4 / base	96.00 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation base_2027q4_sg_sbc	2027Q4 / base	16.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A base_2027q4_sg	2027Q4 / base	112.00 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(base_2027q4_sg_cash, base_2027q4_sg_sbc).
R&D including equity compensation base_2027q4_rd	2027Q4 / base	57.50 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense base_2027q4_ipr	2027Q4 / base	2.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs base_2027q4_ng_opex	2027Q4 / base	171.50 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(base_2027q4_sg, base_2027q4_rd, base_2027q4_ipr).
Non-GAAP operating income base_2027q4_non_gaap_op	2027Q4 / base	43.88 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(base_2027q4_ng_gross_profit, base_2027q4_ng_opex).
Specific cash legal and integration costs base_2027q4_special	2027Q4 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization base_2027q4_op_before_special	2027Q4 / base	39.68 USD_millions	derived: Same amortization as gross profit. Formula: subtract(base_2027q4_non_gaap_op, base_2027q4_acquired_amort).
GAAP operating income base_2027q4_operating_income	2027Q4 / base	37.68 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(base_2027q4_op_before_special, base_2027q4_special).
R&D and COGS equity compensation base_2027q4_other_sbc	2027Q4 / base	7.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation base_2027q4_sbc	2027Q4 / base	23.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(base_2027q4_sg_sbc, base_2027q4_other_sbc).
Other depreciation base_2027q4_depreciation	2027Q4 / base	4.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest base_2027q4_net_interest	2027Q4 / base	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes base_2027q4_cash_before_uses	2027Q4 / base	70.08 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(base_2027q4_operating_income, base_2027q4_sbc, base_2027q4_acquired_amort, base_2027q4_depreciation, base_2027q4_net_interest).
Net working-capital use / sales base_2027q4_wc_ratio	2027Q4 / base	9.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use base_2027q4_wc	2027Q4 / base	22.94 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(base_2027q4_revenue, base_2027q4_wc_ratio).
Cash taxes base_2027q4_tax	2027Q4 / base	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes base_2027q4_operating_cash_uses	2027Q4 / base	23.64 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(base_2027q4_wc, base_2027q4_tax).
Operating cash flow base_2027q4_cfo	2027Q4 / base	46.44 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(base_2027q4_cash_before_uses, base_2027q4_operating_cash_uses).
PP&E including construction spending base_2027q4_capex	2027Q4 / base	18.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex base_2027q4_fcf	2027Q4 / base	28.44 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(base_2027q4_cfo, base_2027q4_capex).
Company-owned life insurance purchases base_2027q4_life_insurance	2027Q4 / base	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding base_2027q4_award_cash	2027Q4 / base	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal base_2027q4_lease_principal	2027Q4 / base	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses base_2027q4_other_cash	2027Q4 / base	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(base_2027q4_life_insurance, base_2027q4_award_cash, base_2027q4_lease_principal).
Cash after other cash uses base_2027q4_cash_after_claims	2027Q4 / base	21.59 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(base_2027q4_fcf, base_2027q4_other_cash).
Revenue ($M) base_fy2026_revenue	FY2026 / base	690.00 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_revenue, base_2026q3_revenue, base_2026q4_revenue).
GAAP gross profit proxy ($M) base_fy2026_gross_profit	FY2026 / base	557.20 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_gross_profit, base_2026q3_gross_profit, base_2026q4_gross_profit).
Non-GAAP operating income proxy ($M) base_fy2026_non_gaap_op	FY2026 / base	-11.90 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_non_gaap_op, base_2026q3_non_gaap_op, base_2026q4_non_gaap_op).
GAAP operating income proxy ($M) base_fy2026_operating_income	FY2026 / base	-48.55 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_operating_income, base_2026q3_operating_income, base_2026q4_operating_income).
Operating cash flow ($M) base_fy2026_cfo	FY2026 / base	15.63 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cfo, base_2026q3_cfo, base_2026q4_cfo).
PP&E and construction cash ($M) base_fy2026_capex	FY2026 / base	25.70 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_capex, base_2026q3_capex, base_2026q4_capex).
CFO less capex ($M) base_fy2026_fcf	FY2026 / base	-10.07 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_fcf, base_2026q3_fcf, base_2026q4_fcf).
Cash after capex and other cash uses ($M) base_fy2026_cash_after_claims	FY2026 / base	-36.71 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cash_after_claims, base_2026q3_cash_after_claims, base_2026q4_cash_after_claims).
Revenue ($M) base_fy2027_revenue	FY2027 / base	910.30 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_revenue, base_2027q2_revenue, base_2027q3_revenue, base_2027q4_revenue).
GAAP gross profit proxy ($M) base_fy2027_gross_profit	FY2027 / base	752.40 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_gross_profit, base_2027q2_gross_profit, base_2027q3_gross_profit, base_2027q4_gross_profit).
Non-GAAP operating income proxy ($M) base_fy2027_non_gaap_op	FY2027 / base	119.50 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_non_gaap_op, base_2027q2_non_gaap_op, base_2027q3_non_gaap_op, base_2027q4_non_gaap_op).
GAAP operating income proxy ($M) base_fy2027_operating_income	FY2027 / base	94.70 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_operating_income, base_2027q2_operating_income, base_2027q3_operating_income, base_2027q4_operating_income).
Operating cash flow ($M) base_fy2027_cfo	FY2027 / base	133.57 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_cfo, base_2027q2_cfo, base_2027q3_cfo, base_2027q4_cfo).
PP&E and construction cash ($M) base_fy2027_capex	FY2027 / base	62.00 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_capex, base_2027q2_capex, base_2027q3_capex, base_2027q4_capex).
CFO less capex ($M) base_fy2027_fcf	FY2027 / base	71.57 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_fcf, base_2027q2_fcf, base_2027q3_fcf, base_2027q4_fcf).
Cash after capex and other cash uses ($M) base_fy2027_cash_after_claims	FY2027 / base	44.17 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(base_2027q1_cash_after_claims, base_2027q2_cash_after_claims, base_2027q3_cash_after_claims, base_2027q4_cash_after_claims).
Annual sales / guidance midpoint upside_delivery	FY2026 / upside	107.0% ratio	assumption: Desk delivery and market-access sensitivity.
Annual revenue scenario upside_target	FY2026 / upside	738.30 USD_millions	derived: Nominal revenue including FX. Formula: multiply(annual_guide, upside_delivery).
Remaining H2 revenue upside_h2	H2 2026 / upside	402.12 USD_millions	derived: Annual scenario less reported H1. Formula: subtract(upside_target, h1_revenue).
Share of H2 sales upside_2026q3_h2_weight	2026Q3 / upside	47.0% ratio	assumption: Desk assumption, not company guidance.
Revenue upside_2026q3_revenue	2026Q3 / upside	189.00 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(upside_h2, upside_2026q3_h2_weight).
idose mix upside_2026q3_idose_mix	2026Q3 / upside	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2026q3_idose	2026Q3 / upside	81.27 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q3_revenue, upside_2026q3_idose_mix).
us_other mix upside_2026q3_us_other_mix	2026Q3 / upside	24.5% ratio	assumption: Desk assumption, not company guidance.
us other revenue upside_2026q3_us_other	2026Q3 / upside	46.30 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q3_revenue, upside_2026q3_us_other_mix).
international mix upside_2026q3_international_mix	2026Q3 / upside	21.0% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2026q3_international	2026Q3 / upside	39.69 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q3_revenue, upside_2026q3_international_mix).
corneal mix upside_2026q3_corneal_mix	2026Q3 / upside	11.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue upside_2026q3_corneal	2026Q3 / upside	21.73 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q3_revenue, upside_2026q3_corneal_mix).
Epioxa share of corneal upside_2026q3_epioxa_mix	2026Q3 / upside	55.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue upside_2026q3_epioxa	2026Q3 / upside	11.95 USD_millions	derived: Subset of corneal health. Formula: multiply(upside_2026q3_corneal, upside_2026q3_epioxa_mix).
Other corneal revenue upside_2026q3_corneal_other	2026Q3 / upside	9.78 USD_millions	derived: No Epioxa double counting. Formula: subtract(upside_2026q3_corneal, upside_2026q3_epioxa).
Non-GAAP gross margin upside_2026q3_ng_gm	2026Q3 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2026q3_ng_gross_profit	2026Q3 / upside	162.54 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2026q3_revenue, upside_2026q3_ng_gm).
Acquired amortization in COGS upside_2026q3_acquired_amort	2026Q3 / upside	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2026q3_gross_profit	2026Q3 / upside	157.24 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2026q3_ng_gross_profit, upside_2026q3_acquired_amort).
SG&A excluding stock compensation upside_2026q3_sg_cash	2026Q3 / upside	82.00 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2026q3_sg_sbc	2026Q3 / upside	13.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2026q3_sg	2026Q3 / upside	95.00 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2026q3_sg_cash, upside_2026q3_sg_sbc).
R&D including equity compensation upside_2026q3_rd	2026Q3 / upside	51.00 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2026q3_ipr	2026Q3 / upside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2026q3_ng_opex	2026Q3 / upside	146.00 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2026q3_sg, upside_2026q3_rd, upside_2026q3_ipr).
Non-GAAP operating income upside_2026q3_non_gaap_op	2026Q3 / upside	16.54 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2026q3_ng_gross_profit, upside_2026q3_ng_opex).
Specific cash legal and integration costs upside_2026q3_special	2026Q3 / upside	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2026q3_op_before_special	2026Q3 / upside	11.24 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2026q3_non_gaap_op, upside_2026q3_acquired_amort).
GAAP operating income upside_2026q3_operating_income	2026Q3 / upside	7.74 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2026q3_op_before_special, upside_2026q3_special).
R&D and COGS equity compensation upside_2026q3_other_sbc	2026Q3 / upside	6.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2026q3_sbc	2026Q3 / upside	19.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2026q3_sg_sbc, upside_2026q3_other_sbc).
Other depreciation upside_2026q3_depreciation	2026Q3 / upside	3.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2026q3_net_interest	2026Q3 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2026q3_cash_before_uses	2026Q3 / upside	36.24 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2026q3_operating_income, upside_2026q3_sbc, upside_2026q3_acquired_amort, upside_2026q3_depreciation, upside_2026q3_net_interest).
Net working-capital use / sales upside_2026q3_wc_ratio	2026Q3 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2026q3_wc	2026Q3 / upside	11.34 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2026q3_revenue, upside_2026q3_wc_ratio).
Cash taxes upside_2026q3_tax	2026Q3 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2026q3_operating_cash_uses	2026Q3 / upside	12.04 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2026q3_wc, upside_2026q3_tax).
Operating cash flow upside_2026q3_cfo	2026Q3 / upside	24.20 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2026q3_cash_before_uses, upside_2026q3_operating_cash_uses).
PP&E including construction spending upside_2026q3_capex	2026Q3 / upside	9.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2026q3_fcf	2026Q3 / upside	15.20 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2026q3_cfo, upside_2026q3_capex).
Company-owned life insurance purchases upside_2026q3_life_insurance	2026Q3 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2026q3_award_cash	2026Q3 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2026q3_lease_principal	2026Q3 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2026q3_other_cash	2026Q3 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2026q3_life_insurance, upside_2026q3_award_cash, upside_2026q3_lease_principal).
Cash after other cash uses upside_2026q3_cash_after_claims	2026Q3 / upside	8.35 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2026q3_fcf, upside_2026q3_other_cash).
Share of H2 sales upside_2026q4_h2_weight	2026Q4 / upside	53.0% ratio	assumption: Desk assumption, not company guidance.
Revenue upside_2026q4_revenue	2026Q4 / upside	213.12 USD_millions	derived: Q3 reflects disclosed corneal transition risk; allocation is a desk assumption. Formula: multiply(upside_h2, upside_2026q4_h2_weight).
idose mix upside_2026q4_idose_mix	2026Q4 / upside	43.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2026q4_idose	2026Q4 / upside	91.64 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q4_revenue, upside_2026q4_idose_mix).
us_other mix upside_2026q4_us_other_mix	2026Q4 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
us other revenue upside_2026q4_us_other	2026Q4 / upside	51.15 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q4_revenue, upside_2026q4_us_other_mix).
international mix upside_2026q4_international_mix	2026Q4 / upside	19.5% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2026q4_international	2026Q4 / upside	41.56 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q4_revenue, upside_2026q4_international_mix).
corneal mix upside_2026q4_corneal_mix	2026Q4 / upside	13.5% ratio	assumption: Desk assumption, not company guidance.
corneal revenue upside_2026q4_corneal	2026Q4 / upside	28.77 USD_millions	derived: Product/geography mix sensitivity, not a company forecast. Formula: multiply(upside_2026q4_revenue, upside_2026q4_corneal_mix).
Epioxa share of corneal upside_2026q4_epioxa_mix	2026Q4 / upside	72.0% ratio	assumption: Desk assumption, not company guidance.
Epioxa revenue upside_2026q4_epioxa	2026Q4 / upside	20.72 USD_millions	derived: Subset of corneal health. Formula: multiply(upside_2026q4_corneal, upside_2026q4_epioxa_mix).
Other corneal revenue upside_2026q4_corneal_other	2026Q4 / upside	8.06 USD_millions	derived: No Epioxa double counting. Formula: subtract(upside_2026q4_corneal, upside_2026q4_epioxa).
Non-GAAP gross margin upside_2026q4_ng_gm	2026Q4 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2026q4_ng_gross_profit	2026Q4 / upside	183.29 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2026q4_revenue, upside_2026q4_ng_gm).
Acquired amortization in COGS upside_2026q4_acquired_amort	2026Q4 / upside	5.30 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2026q4_gross_profit	2026Q4 / upside	177.99 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2026q4_ng_gross_profit, upside_2026q4_acquired_amort).
SG&A excluding stock compensation upside_2026q4_sg_cash	2026Q4 / upside	85.28 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2026q4_sg_sbc	2026Q4 / upside	13.60 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2026q4_sg	2026Q4 / upside	98.88 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2026q4_sg_cash, upside_2026q4_sg_sbc).
R&D including equity compensation upside_2026q4_rd	2026Q4 / upside	52.53 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2026q4_ipr	2026Q4 / upside	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2026q4_ng_opex	2026Q4 / upside	152.91 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2026q4_sg, upside_2026q4_rd, upside_2026q4_ipr).
Non-GAAP operating income upside_2026q4_non_gaap_op	2026Q4 / upside	30.38 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2026q4_ng_gross_profit, upside_2026q4_ng_opex).
Specific cash legal and integration costs upside_2026q4_special	2026Q4 / upside	3.50 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2026q4_op_before_special	2026Q4 / upside	25.08 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2026q4_non_gaap_op, upside_2026q4_acquired_amort).
GAAP operating income upside_2026q4_operating_income	2026Q4 / upside	21.58 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2026q4_op_before_special, upside_2026q4_special).
R&D and COGS equity compensation upside_2026q4_other_sbc	2026Q4 / upside	6.70 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2026q4_sbc	2026Q4 / upside	20.30 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2026q4_sg_sbc, upside_2026q4_other_sbc).
Other depreciation upside_2026q4_depreciation	2026Q4 / upside	3.40 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2026q4_net_interest	2026Q4 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2026q4_cash_before_uses	2026Q4 / upside	51.08 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2026q4_operating_income, upside_2026q4_sbc, upside_2026q4_acquired_amort, upside_2026q4_depreciation, upside_2026q4_net_interest).
Net working-capital use / sales upside_2026q4_wc_ratio	2026Q4 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2026q4_wc	2026Q4 / upside	12.79 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2026q4_revenue, upside_2026q4_wc_ratio).
Cash taxes upside_2026q4_tax	2026Q4 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2026q4_operating_cash_uses	2026Q4 / upside	13.49 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2026q4_wc, upside_2026q4_tax).
Operating cash flow upside_2026q4_cfo	2026Q4 / upside	37.59 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2026q4_cash_before_uses, upside_2026q4_operating_cash_uses).
PP&E including construction spending upside_2026q4_capex	2026Q4 / upside	12.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2026q4_fcf	2026Q4 / upside	25.59 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2026q4_cfo, upside_2026q4_capex).
Company-owned life insurance purchases upside_2026q4_life_insurance	2026Q4 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2026q4_award_cash	2026Q4 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2026q4_lease_principal	2026Q4 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2026q4_other_cash	2026Q4 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2026q4_life_insurance, upside_2026q4_award_cash, upside_2026q4_lease_principal).
Cash after other cash uses upside_2026q4_cash_after_claims	2026Q4 / upside	18.74 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2026q4_fcf, upside_2026q4_other_cash).
Prior H2 idose upside_2027q1_idose_h2	2027Q1 / upside	172.91 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_idose, upside_2026q4_idose).
Half-year annualization upside_2027q1_idose_annualize	2027Q1 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q1_idose_growth	2027Q1 / upside	165.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q1_idose_season	2027Q1 / upside	23.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2027q1_idose	2027Q1 / upside	131.24 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q1_idose_h2, upside_2027q1_idose_annualize, upside_2027q1_idose_growth, upside_2027q1_idose_season).
Prior H2 us_other upside_2027q1_us_other_h2	2027Q1 / upside	97.45 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_us_other, upside_2026q4_us_other).
Half-year annualization upside_2027q1_us_other_annualize	2027Q1 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q1_us_other_growth	2027Q1 / upside	108.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q1_us_other_season	2027Q1 / upside	23.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue upside_2027q1_us_other	2027Q1 / upside	48.41 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q1_us_other_h2, upside_2027q1_us_other_annualize, upside_2027q1_us_other_growth, upside_2027q1_us_other_season).
Prior H2 international upside_2027q1_international_h2	2027Q1 / upside	81.25 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_international, upside_2026q4_international).
Half-year annualization upside_2027q1_international_annualize	2027Q1 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q1_international_growth	2027Q1 / upside	122.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q1_international_season	2027Q1 / upside	23.0% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2027q1_international	2027Q1 / upside	45.60 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q1_international_h2, upside_2027q1_international_annualize, upside_2027q1_international_growth, upside_2027q1_international_season).
Prior H2 epioxa upside_2027q1_epioxa_h2	2027Q1 / upside	32.67 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_epioxa, upside_2026q4_epioxa).
Half-year annualization upside_2027q1_epioxa_annualize	2027Q1 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q1_epioxa_growth	2027Q1 / upside	250.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q1_epioxa_season	2027Q1 / upside	23.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue upside_2027q1_epioxa	2027Q1 / upside	37.57 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q1_epioxa_h2, upside_2027q1_epioxa_annualize, upside_2027q1_epioxa_growth, upside_2027q1_epioxa_season).
Prior H2 corneal_other upside_2027q1_corneal_other_h2	2027Q1 / upside	17.84 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_corneal_other, upside_2026q4_corneal_other).
Half-year annualization upside_2027q1_corneal_other_annualize	2027Q1 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q1_corneal_other_growth	2027Q1 / upside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q1_corneal_other_season	2027Q1 / upside	23.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue upside_2027q1_corneal_other	2027Q1 / upside	7.38 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q1_corneal_other_h2, upside_2027q1_corneal_other_annualize, upside_2027q1_corneal_other_growth, upside_2027q1_corneal_other_season).
Revenue upside_2027q1_revenue	2027Q1 / upside	270.21 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(upside_2027q1_idose, upside_2027q1_us_other, upside_2027q1_international, upside_2027q1_epioxa, upside_2027q1_corneal_other).
Non-GAAP gross margin upside_2027q1_ng_gm	2027Q1 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2027q1_ng_gross_profit	2027Q1 / upside	232.38 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2027q1_revenue, upside_2027q1_ng_gm).
Acquired amortization in COGS upside_2027q1_acquired_amort	2027Q1 / upside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2027q1_gross_profit	2027Q1 / upside	228.18 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2027q1_ng_gross_profit, upside_2027q1_acquired_amort).
SG&A excluding stock compensation upside_2027q1_sg_cash	2027Q1 / upside	88.56 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2027q1_sg_sbc	2027Q1 / upside	14.20 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2027q1_sg	2027Q1 / upside	102.76 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2027q1_sg_cash, upside_2027q1_sg_sbc).
R&D including equity compensation upside_2027q1_rd	2027Q1 / upside	54.06 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2027q1_ipr	2027Q1 / upside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2027q1_ng_opex	2027Q1 / upside	156.82 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2027q1_sg, upside_2027q1_rd, upside_2027q1_ipr).
Non-GAAP operating income upside_2027q1_non_gaap_op	2027Q1 / upside	75.56 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2027q1_ng_gross_profit, upside_2027q1_ng_opex).
Specific cash legal and integration costs upside_2027q1_special	2027Q1 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2027q1_op_before_special	2027Q1 / upside	71.36 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2027q1_non_gaap_op, upside_2027q1_acquired_amort).
GAAP operating income upside_2027q1_operating_income	2027Q1 / upside	69.36 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2027q1_op_before_special, upside_2027q1_special).
R&D and COGS equity compensation upside_2027q1_other_sbc	2027Q1 / upside	6.90 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2027q1_sbc	2027Q1 / upside	21.10 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2027q1_sg_sbc, upside_2027q1_other_sbc).
Other depreciation upside_2027q1_depreciation	2027Q1 / upside	3.60 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2027q1_net_interest	2027Q1 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2027q1_cash_before_uses	2027Q1 / upside	98.76 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2027q1_operating_income, upside_2027q1_sbc, upside_2027q1_acquired_amort, upside_2027q1_depreciation, upside_2027q1_net_interest).
Net working-capital use / sales upside_2027q1_wc_ratio	2027Q1 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2027q1_wc	2027Q1 / upside	16.21 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2027q1_revenue, upside_2027q1_wc_ratio).
Cash taxes upside_2027q1_tax	2027Q1 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2027q1_operating_cash_uses	2027Q1 / upside	16.91 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2027q1_wc, upside_2027q1_tax).
Operating cash flow upside_2027q1_cfo	2027Q1 / upside	81.84 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2027q1_cash_before_uses, upside_2027q1_operating_cash_uses).
PP&E including construction spending upside_2027q1_capex	2027Q1 / upside	14.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2027q1_fcf	2027Q1 / upside	67.84 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2027q1_cfo, upside_2027q1_capex).
Company-owned life insurance purchases upside_2027q1_life_insurance	2027Q1 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2027q1_award_cash	2027Q1 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2027q1_lease_principal	2027Q1 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2027q1_other_cash	2027Q1 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2027q1_life_insurance, upside_2027q1_award_cash, upside_2027q1_lease_principal).
Cash after other cash uses upside_2027q1_cash_after_claims	2027Q1 / upside	60.99 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2027q1_fcf, upside_2027q1_other_cash).
Prior H2 idose upside_2027q2_idose_h2	2027Q2 / upside	172.91 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_idose, upside_2026q4_idose).
Half-year annualization upside_2027q2_idose_annualize	2027Q2 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q2_idose_growth	2027Q2 / upside	165.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q2_idose_season	2027Q2 / upside	25.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2027q2_idose	2027Q2 / upside	142.65 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q2_idose_h2, upside_2027q2_idose_annualize, upside_2027q2_idose_growth, upside_2027q2_idose_season).
Prior H2 us_other upside_2027q2_us_other_h2	2027Q2 / upside	97.45 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_us_other, upside_2026q4_us_other).
Half-year annualization upside_2027q2_us_other_annualize	2027Q2 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q2_us_other_growth	2027Q2 / upside	108.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q2_us_other_season	2027Q2 / upside	25.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue upside_2027q2_us_other	2027Q2 / upside	52.62 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q2_us_other_h2, upside_2027q2_us_other_annualize, upside_2027q2_us_other_growth, upside_2027q2_us_other_season).
Prior H2 international upside_2027q2_international_h2	2027Q2 / upside	81.25 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_international, upside_2026q4_international).
Half-year annualization upside_2027q2_international_annualize	2027Q2 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q2_international_growth	2027Q2 / upside	122.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q2_international_season	2027Q2 / upside	25.0% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2027q2_international	2027Q2 / upside	49.56 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q2_international_h2, upside_2027q2_international_annualize, upside_2027q2_international_growth, upside_2027q2_international_season).
Prior H2 epioxa upside_2027q2_epioxa_h2	2027Q2 / upside	32.67 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_epioxa, upside_2026q4_epioxa).
Half-year annualization upside_2027q2_epioxa_annualize	2027Q2 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q2_epioxa_growth	2027Q2 / upside	250.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q2_epioxa_season	2027Q2 / upside	25.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue upside_2027q2_epioxa	2027Q2 / upside	40.84 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q2_epioxa_h2, upside_2027q2_epioxa_annualize, upside_2027q2_epioxa_growth, upside_2027q2_epioxa_season).
Prior H2 corneal_other upside_2027q2_corneal_other_h2	2027Q2 / upside	17.84 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_corneal_other, upside_2026q4_corneal_other).
Half-year annualization upside_2027q2_corneal_other_annualize	2027Q2 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q2_corneal_other_growth	2027Q2 / upside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q2_corneal_other_season	2027Q2 / upside	25.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue upside_2027q2_corneal_other	2027Q2 / upside	8.03 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q2_corneal_other_h2, upside_2027q2_corneal_other_annualize, upside_2027q2_corneal_other_growth, upside_2027q2_corneal_other_season).
Revenue upside_2027q2_revenue	2027Q2 / upside	293.70 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(upside_2027q2_idose, upside_2027q2_us_other, upside_2027q2_international, upside_2027q2_epioxa, upside_2027q2_corneal_other).
Non-GAAP gross margin upside_2027q2_ng_gm	2027Q2 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2027q2_ng_gross_profit	2027Q2 / upside	252.58 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2027q2_revenue, upside_2027q2_ng_gm).
Acquired amortization in COGS upside_2027q2_acquired_amort	2027Q2 / upside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2027q2_gross_profit	2027Q2 / upside	248.38 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2027q2_ng_gross_profit, upside_2027q2_acquired_amort).
SG&A excluding stock compensation upside_2027q2_sg_cash	2027Q2 / upside	91.84 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2027q2_sg_sbc	2027Q2 / upside	14.80 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2027q2_sg	2027Q2 / upside	106.64 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2027q2_sg_cash, upside_2027q2_sg_sbc).
R&D including equity compensation upside_2027q2_rd	2027Q2 / upside	55.59 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2027q2_ipr	2027Q2 / upside	1.50 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2027q2_ng_opex	2027Q2 / upside	163.73 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2027q2_sg, upside_2027q2_rd, upside_2027q2_ipr).
Non-GAAP operating income upside_2027q2_non_gaap_op	2027Q2 / upside	88.85 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2027q2_ng_gross_profit, upside_2027q2_ng_opex).
Specific cash legal and integration costs upside_2027q2_special	2027Q2 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2027q2_op_before_special	2027Q2 / upside	84.65 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2027q2_non_gaap_op, upside_2027q2_acquired_amort).
GAAP operating income upside_2027q2_operating_income	2027Q2 / upside	82.65 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2027q2_op_before_special, upside_2027q2_special).
R&D and COGS equity compensation upside_2027q2_other_sbc	2027Q2 / upside	7.10 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2027q2_sbc	2027Q2 / upside	21.90 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2027q2_sg_sbc, upside_2027q2_other_sbc).
Other depreciation upside_2027q2_depreciation	2027Q2 / upside	3.80 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2027q2_net_interest	2027Q2 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2027q2_cash_before_uses	2027Q2 / upside	113.05 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2027q2_operating_income, upside_2027q2_sbc, upside_2027q2_acquired_amort, upside_2027q2_depreciation, upside_2027q2_net_interest).
Net working-capital use / sales upside_2027q2_wc_ratio	2027Q2 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2027q2_wc	2027Q2 / upside	17.62 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2027q2_revenue, upside_2027q2_wc_ratio).
Cash taxes upside_2027q2_tax	2027Q2 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2027q2_operating_cash_uses	2027Q2 / upside	18.32 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2027q2_wc, upside_2027q2_tax).
Operating cash flow upside_2027q2_cfo	2027Q2 / upside	94.73 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2027q2_cash_before_uses, upside_2027q2_operating_cash_uses).
PP&E including construction spending upside_2027q2_capex	2027Q2 / upside	16.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2027q2_fcf	2027Q2 / upside	78.73 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2027q2_cfo, upside_2027q2_capex).
Company-owned life insurance purchases upside_2027q2_life_insurance	2027Q2 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2027q2_award_cash	2027Q2 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2027q2_lease_principal	2027Q2 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2027q2_other_cash	2027Q2 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2027q2_life_insurance, upside_2027q2_award_cash, upside_2027q2_lease_principal).
Cash after other cash uses upside_2027q2_cash_after_claims	2027Q2 / upside	71.88 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2027q2_fcf, upside_2027q2_other_cash).
Prior H2 idose upside_2027q3_idose_h2	2027Q3 / upside	172.91 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_idose, upside_2026q4_idose).
Half-year annualization upside_2027q3_idose_annualize	2027Q3 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q3_idose_growth	2027Q3 / upside	165.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q3_idose_season	2027Q3 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2027q3_idose	2027Q3 / upside	136.95 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q3_idose_h2, upside_2027q3_idose_annualize, upside_2027q3_idose_growth, upside_2027q3_idose_season).
Prior H2 us_other upside_2027q3_us_other_h2	2027Q3 / upside	97.45 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_us_other, upside_2026q4_us_other).
Half-year annualization upside_2027q3_us_other_annualize	2027Q3 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q3_us_other_growth	2027Q3 / upside	108.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q3_us_other_season	2027Q3 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue upside_2027q3_us_other	2027Q3 / upside	50.52 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q3_us_other_h2, upside_2027q3_us_other_annualize, upside_2027q3_us_other_growth, upside_2027q3_us_other_season).
Prior H2 international upside_2027q3_international_h2	2027Q3 / upside	81.25 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_international, upside_2026q4_international).
Half-year annualization upside_2027q3_international_annualize	2027Q3 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q3_international_growth	2027Q3 / upside	122.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q3_international_season	2027Q3 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2027q3_international	2027Q3 / upside	47.58 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q3_international_h2, upside_2027q3_international_annualize, upside_2027q3_international_growth, upside_2027q3_international_season).
Prior H2 epioxa upside_2027q3_epioxa_h2	2027Q3 / upside	32.67 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_epioxa, upside_2026q4_epioxa).
Half-year annualization upside_2027q3_epioxa_annualize	2027Q3 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q3_epioxa_growth	2027Q3 / upside	250.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q3_epioxa_season	2027Q3 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue upside_2027q3_epioxa	2027Q3 / upside	39.20 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q3_epioxa_h2, upside_2027q3_epioxa_annualize, upside_2027q3_epioxa_growth, upside_2027q3_epioxa_season).
Prior H2 corneal_other upside_2027q3_corneal_other_h2	2027Q3 / upside	17.84 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_corneal_other, upside_2026q4_corneal_other).
Half-year annualization upside_2027q3_corneal_other_annualize	2027Q3 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q3_corneal_other_growth	2027Q3 / upside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q3_corneal_other_season	2027Q3 / upside	24.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue upside_2027q3_corneal_other	2027Q3 / upside	7.71 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q3_corneal_other_h2, upside_2027q3_corneal_other_annualize, upside_2027q3_corneal_other_growth, upside_2027q3_corneal_other_season).
Revenue upside_2027q3_revenue	2027Q3 / upside	281.95 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(upside_2027q3_idose, upside_2027q3_us_other, upside_2027q3_international, upside_2027q3_epioxa, upside_2027q3_corneal_other).
Non-GAAP gross margin upside_2027q3_ng_gm	2027Q3 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2027q3_ng_gross_profit	2027Q3 / upside	242.48 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2027q3_revenue, upside_2027q3_ng_gm).
Acquired amortization in COGS upside_2027q3_acquired_amort	2027Q3 / upside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2027q3_gross_profit	2027Q3 / upside	238.28 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2027q3_ng_gross_profit, upside_2027q3_acquired_amort).
SG&A excluding stock compensation upside_2027q3_sg_cash	2027Q3 / upside	95.12 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2027q3_sg_sbc	2027Q3 / upside	15.40 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2027q3_sg	2027Q3 / upside	110.52 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2027q3_sg_cash, upside_2027q3_sg_sbc).
R&D including equity compensation upside_2027q3_rd	2027Q3 / upside	57.12 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2027q3_ipr	2027Q3 / upside	0.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2027q3_ng_opex	2027Q3 / upside	167.64 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2027q3_sg, upside_2027q3_rd, upside_2027q3_ipr).
Non-GAAP operating income upside_2027q3_non_gaap_op	2027Q3 / upside	74.84 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2027q3_ng_gross_profit, upside_2027q3_ng_opex).
Specific cash legal and integration costs upside_2027q3_special	2027Q3 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2027q3_op_before_special	2027Q3 / upside	70.64 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2027q3_non_gaap_op, upside_2027q3_acquired_amort).
GAAP operating income upside_2027q3_operating_income	2027Q3 / upside	68.64 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2027q3_op_before_special, upside_2027q3_special).
R&D and COGS equity compensation upside_2027q3_other_sbc	2027Q3 / upside	7.30 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2027q3_sbc	2027Q3 / upside	22.70 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2027q3_sg_sbc, upside_2027q3_other_sbc).
Other depreciation upside_2027q3_depreciation	2027Q3 / upside	4.00 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2027q3_net_interest	2027Q3 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2027q3_cash_before_uses	2027Q3 / upside	100.04 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2027q3_operating_income, upside_2027q3_sbc, upside_2027q3_acquired_amort, upside_2027q3_depreciation, upside_2027q3_net_interest).
Net working-capital use / sales upside_2027q3_wc_ratio	2027Q3 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2027q3_wc	2027Q3 / upside	16.92 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2027q3_revenue, upside_2027q3_wc_ratio).
Cash taxes upside_2027q3_tax	2027Q3 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2027q3_operating_cash_uses	2027Q3 / upside	17.62 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2027q3_wc, upside_2027q3_tax).
Operating cash flow upside_2027q3_cfo	2027Q3 / upside	82.42 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2027q3_cash_before_uses, upside_2027q3_operating_cash_uses).
PP&E including construction spending upside_2027q3_capex	2027Q3 / upside	18.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2027q3_fcf	2027Q3 / upside	64.42 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2027q3_cfo, upside_2027q3_capex).
Company-owned life insurance purchases upside_2027q3_life_insurance	2027Q3 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2027q3_award_cash	2027Q3 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2027q3_lease_principal	2027Q3 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2027q3_other_cash	2027Q3 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2027q3_life_insurance, upside_2027q3_award_cash, upside_2027q3_lease_principal).
Cash after other cash uses upside_2027q3_cash_after_claims	2027Q3 / upside	57.57 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2027q3_fcf, upside_2027q3_other_cash).
Prior H2 idose upside_2027q4_idose_h2	2027Q4 / upside	172.91 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_idose, upside_2026q4_idose).
Half-year annualization upside_2027q4_idose_annualize	2027Q4 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q4_idose_growth	2027Q4 / upside	165.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q4_idose_season	2027Q4 / upside	28.0% ratio	assumption: Desk assumption, not company guidance.
idose revenue upside_2027q4_idose	2027Q4 / upside	159.77 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q4_idose_h2, upside_2027q4_idose_annualize, upside_2027q4_idose_growth, upside_2027q4_idose_season).
Prior H2 us_other upside_2027q4_us_other_h2	2027Q4 / upside	97.45 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_us_other, upside_2026q4_us_other).
Half-year annualization upside_2027q4_us_other_annualize	2027Q4 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q4_us_other_growth	2027Q4 / upside	108.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q4_us_other_season	2027Q4 / upside	28.0% ratio	assumption: Desk assumption, not company guidance.
us_other revenue upside_2027q4_us_other	2027Q4 / upside	58.94 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q4_us_other_h2, upside_2027q4_us_other_annualize, upside_2027q4_us_other_growth, upside_2027q4_us_other_season).
Prior H2 international upside_2027q4_international_h2	2027Q4 / upside	81.25 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_international, upside_2026q4_international).
Half-year annualization upside_2027q4_international_annualize	2027Q4 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q4_international_growth	2027Q4 / upside	122.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q4_international_season	2027Q4 / upside	28.0% ratio	assumption: Desk assumption, not company guidance.
international revenue upside_2027q4_international	2027Q4 / upside	55.51 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q4_international_h2, upside_2027q4_international_annualize, upside_2027q4_international_growth, upside_2027q4_international_season).
Prior H2 epioxa upside_2027q4_epioxa_h2	2027Q4 / upside	32.67 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_epioxa, upside_2026q4_epioxa).
Half-year annualization upside_2027q4_epioxa_annualize	2027Q4 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q4_epioxa_growth	2027Q4 / upside	250.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q4_epioxa_season	2027Q4 / upside	28.0% ratio	assumption: Desk assumption, not company guidance.
epioxa revenue upside_2027q4_epioxa	2027Q4 / upside	45.74 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q4_epioxa_h2, upside_2027q4_epioxa_annualize, upside_2027q4_epioxa_growth, upside_2027q4_epioxa_season).
Prior H2 corneal_other upside_2027q4_corneal_other_h2	2027Q4 / upside	17.84 USD_millions	derived: Known model reference, not reported product history. Formula: sum(upside_2026q3_corneal_other, upside_2026q4_corneal_other).
Half-year annualization upside_2027q4_corneal_other_annualize	2027Q4 / upside	200.0% ratio	assumption: Desk assumption, not company guidance.
Business-line expansion upside_2027q4_corneal_other_growth	2027Q4 / upside	90.0% ratio	assumption: Desk assumption, not company guidance.
Quarter share upside_2027q4_corneal_other_season	2027Q4 / upside	28.0% ratio	assumption: Desk assumption, not company guidance.
corneal_other revenue upside_2027q4_corneal_other	2027Q4 / upside	8.99 USD_millions	derived: Separate product adoption and seasonal sensitivity. Formula: multiply(upside_2027q4_corneal_other_h2, upside_2027q4_corneal_other_annualize, upside_2027q4_corneal_other_growth, upside_2027q4_corneal_other_season).
Revenue upside_2027q4_revenue	2027Q4 / upside	328.95 USD_millions	derived: Each product/geographic stream is included once. Formula: sum(upside_2027q4_idose, upside_2027q4_us_other, upside_2027q4_international, upside_2027q4_epioxa, upside_2027q4_corneal_other).
Non-GAAP gross margin upside_2027q4_ng_gm	2027Q4 / upside	86.0% ratio	assumption: Desk assumption, not company guidance.
Non-GAAP gross profit upside_2027q4_ng_gross_profit	2027Q4 / upside	282.89 USD_millions	derived: Includes ordinary stock compensation; acquired amortization excluded. Formula: multiply(upside_2027q4_revenue, upside_2027q4_ng_gm).
Acquired amortization in COGS upside_2027q4_acquired_amort	2027Q4 / upside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
GAAP gross profit upside_2027q4_gross_profit	2027Q4 / upside	278.69 USD_millions	derived: Separate acquired amortization; no SBC exclusion. Formula: subtract(upside_2027q4_ng_gross_profit, upside_2027q4_acquired_amort).
SG&A excluding stock compensation upside_2027q4_sg_cash	2027Q4 / upside	98.40 USD_millions	assumption: Desk assumption, not company guidance.
SG&A stock compensation upside_2027q4_sg_sbc	2027Q4 / upside	16.00 USD_millions	assumption: Desk assumption, not company guidance.
Non-GAAP SG&A upside_2027q4_sg	2027Q4 / upside	114.40 USD_millions	derived: Ordinary stock compensation remains an operating expense. Formula: sum(upside_2027q4_sg_cash, upside_2027q4_sg_sbc).
R&D including equity compensation upside_2027q4_rd	2027Q4 / upside	58.65 USD_millions	assumption: Desk assumption, not company guidance.
Acquired research/milestone expense upside_2027q4_ipr	2027Q4 / upside	2.00 USD_millions	assumption: Contingent desk allowance, not a scheduled disclosed milestone.
Non-GAAP operating costs upside_2027q4_ng_opex	2027Q4 / upside	175.05 USD_millions	derived: Includes research milestone expense exactly once. Formula: sum(upside_2027q4_sg, upside_2027q4_rd, upside_2027q4_ipr).
Non-GAAP operating income upside_2027q4_non_gaap_op	2027Q4 / upside	107.84 USD_millions	derived: Ordinary SBC and IPR&D are retained. Formula: subtract(upside_2027q4_ng_gross_profit, upside_2027q4_ng_opex).
Specific cash legal and integration costs upside_2027q4_special	2027Q4 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Profit after acquired amortization upside_2027q4_op_before_special	2027Q4 / upside	103.64 USD_millions	derived: Same amortization as gross profit. Formula: subtract(upside_2027q4_non_gaap_op, upside_2027q4_acquired_amort).
GAAP operating income upside_2027q4_operating_income	2027Q4 / upside	101.64 USD_millions	derived: Specific cash costs remain in CFO. Formula: subtract(upside_2027q4_op_before_special, upside_2027q4_special).
R&D and COGS equity compensation upside_2027q4_other_sbc	2027Q4 / upside	7.50 USD_millions	assumption: Desk assumption, not company guidance.
Total equity compensation upside_2027q4_sbc	2027Q4 / upside	23.50 USD_millions	derived: Noncash operating expenses reverse once in cash flow. Formula: sum(upside_2027q4_sg_sbc, upside_2027q4_other_sbc).
Other depreciation upside_2027q4_depreciation	2027Q4 / upside	4.20 USD_millions	assumption: Desk assumption, not company guidance.
Cash investment income less finance interest upside_2027q4_net_interest	2027Q4 / upside	0.50 USD_millions	assumption: Desk assumption, not company guidance.
Cash before working capital and taxes upside_2027q4_cash_before_uses	2027Q4 / upside	134.04 USD_millions	derived: Acquired amortization plus ordinary depreciation; operating leases remain in operating costs. Formula: sum(upside_2027q4_operating_income, upside_2027q4_sbc, upside_2027q4_acquired_amort, upside_2027q4_depreciation, upside_2027q4_net_interest).
Net working-capital use / sales upside_2027q4_wc_ratio	2027Q4 / upside	6.0% ratio	assumption: Desk assumption, not company guidance.
Receivable, inventory and other working-capital use upside_2027q4_wc	2027Q4 / upside	19.74 USD_millions	derived: Growth requires collection and inventory funding. Formula: multiply(upside_2027q4_revenue, upside_2027q4_wc_ratio).
Cash taxes upside_2027q4_tax	2027Q4 / upside	0.70 USD_millions	assumption: Desk assumption, not company guidance.
Working capital and cash taxes upside_2027q4_operating_cash_uses	2027Q4 / upside	20.44 USD_millions	derived: Clinical and legal cash costs are already in operating expense. Formula: sum(upside_2027q4_wc, upside_2027q4_tax).
Operating cash flow upside_2027q4_cfo	2027Q4 / upside	113.61 USD_millions	derived: Illustrative cash bridge, not a complete balance sheet. Formula: subtract(upside_2027q4_cash_before_uses, upside_2027q4_operating_cash_uses).
PP&E including construction spending upside_2027q4_capex	2027Q4 / upside	20.00 USD_millions	assumption: Desk assumption, not company guidance.
CFO less capex upside_2027q4_fcf	2027Q4 / upside	93.61 USD_millions	derived: Construction is not hidden in maintenance capex. Formula: subtract(upside_2027q4_cfo, upside_2027q4_capex).
Company-owned life insurance purchases upside_2027q4_life_insurance	2027Q4 / upside	2.00 USD_millions	assumption: Desk assumption, not company guidance.
Equity-award tax withholding upside_2027q4_award_cash	2027Q4 / upside	4.50 USD_millions	assumption: Desk assumption, not company guidance.
Finance lease principal upside_2027q4_lease_principal	2027Q4 / upside	0.35 USD_millions	assumption: Desk assumption, not company guidance.
Other investing and financing cash uses upside_2027q4_other_cash	2027Q4 / upside	6.85 USD_millions	derived: Not additional operating expense. Formula: sum(upside_2027q4_life_insurance, upside_2027q4_award_cash, upside_2027q4_lease_principal).
Cash after other cash uses upside_2027q4_cash_after_claims	2027Q4 / upside	86.76 USD_millions	derived: Before new stock proceeds, debt or acquisitions. Formula: subtract(upside_2027q4_fcf, upside_2027q4_other_cash).
Revenue ($M) upside_fy2026_revenue	FY2026 / upside	738.30 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_revenue, upside_2026q3_revenue, upside_2026q4_revenue).
GAAP gross profit proxy ($M) upside_fy2026_gross_profit	FY2026 / upside	604.05 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_gross_profit, upside_2026q3_gross_profit, upside_2026q4_gross_profit).
Non-GAAP operating income proxy ($M) upside_fy2026_non_gaap_op	FY2026 / upside	28.84 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_non_gaap_op, upside_2026q3_non_gaap_op, upside_2026q4_non_gaap_op).
GAAP operating income proxy ($M) upside_fy2026_operating_income	FY2026 / upside	-7.81 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_operating_income, upside_2026q3_operating_income, upside_2026q4_operating_income).
Operating cash flow ($M) upside_fy2026_cfo	FY2026 / upside	64.08 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cfo, upside_2026q3_cfo, upside_2026q4_cfo).
PP&E and construction cash ($M) upside_fy2026_capex	FY2026 / upside	27.70 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_capex, upside_2026q3_capex, upside_2026q4_capex).
CFO less capex ($M) upside_fy2026_fcf	FY2026 / upside	36.39 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_fcf, upside_2026q3_fcf, upside_2026q4_fcf).
Cash after capex and other cash uses ($M) upside_fy2026_cash_after_claims	FY2026 / upside	9.75 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(h1_cash_after_claims, upside_2026q3_cash_after_claims, upside_2026q4_cash_after_claims).
Revenue ($M) upside_fy2027_revenue	FY2027 / upside	1,174.81 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_revenue, upside_2027q2_revenue, upside_2027q3_revenue, upside_2027q4_revenue).
GAAP gross profit proxy ($M) upside_fy2027_gross_profit	FY2027 / upside	993.53 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_gross_profit, upside_2027q2_gross_profit, upside_2027q3_gross_profit, upside_2027q4_gross_profit).
Non-GAAP operating income proxy ($M) upside_fy2027_non_gaap_op	FY2027 / upside	347.09 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_non_gaap_op, upside_2027q2_non_gaap_op, upside_2027q3_non_gaap_op, upside_2027q4_non_gaap_op).
GAAP operating income proxy ($M) upside_fy2027_operating_income	FY2027 / upside	322.29 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_operating_income, upside_2027q2_operating_income, upside_2027q3_operating_income, upside_2027q4_operating_income).
Operating cash flow ($M) upside_fy2027_cfo	FY2027 / upside	372.60 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_cfo, upside_2027q2_cfo, upside_2027q3_cfo, upside_2027q4_cfo).
PP&E and construction cash ($M) upside_fy2027_capex	FY2027 / upside	68.00 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_capex, upside_2027q2_capex, upside_2027q3_capex, upside_2027q4_capex).
CFO less capex ($M) upside_fy2027_fcf	FY2027 / upside	304.60 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_fcf, upside_2027q2_fcf, upside_2027q3_fcf, upside_2027q4_fcf).
Cash after capex and other cash uses ($M) upside_fy2027_cash_after_claims	FY2027 / upside	277.20 USD_millions	derived: Reported year-to-date amount plus remaining forecast quarters, or sum of four forecast quarters. Formula: sum(upside_2027q1_cash_after_claims, upside_2027q2_cash_after_claims, upside_2027q3_cash_after_claims, upside_2027q4_cash_after_claims).

Model boundaries

Product and geographic forecast splits are desk assumptions; rounded Q2 product disclosures are references, not exact standalone financial statements.
FY2026 nominal revenue guidance includes current FX assumptions. No unapproved pipeline revenue or automatic commercial benefit from proposed reimbursement policies is included.
Non-GAAP operating income retains ordinary stock compensation and acquired IPR&D. The approximately $15M Q2 award trigger is not mechanically repeated every quarter.
The new Huntsville facility is expected to require more than $80M over multiple years. Forecast construction timing is a sensitivity, not a disclosed annual budget; spending extends beyond this horizon.
Historical capex uses PP&E purchases; the separate 2025 real-estate purchase is outside that feed measure. Forecast capex includes assumed construction cash. Cash after other uses is before new financing or acquisitions.
No complete EPS, clinical trial probability, reimbursement-policy forecast or equity valuation is supplied. Sources are reviewed through September 19, 2026.

Launch adoption must fund research and manufacturing

Research reviewed 2026-09-19

Can the expanding ophthalmic franchise finance its commercial, clinical and manufacturing requirements?

H1 sales were $336.181M, GAAP operating loss $37.123M and non-GAAP operating loss $18.077M. Ordinary SBC of $48.009M remains in adjusted operating costs; Q2 included approximately $15M from a performance-award trigger. H1 CFO of $2.297M less $6.697M PP&E was negative $4.400M. Insurance purchases, award withholding and finance-lease principal reduce cash further to negative $17.339M before equity proceeds. Unrestricted cash and investments were $286.226M; $3.115M restricted cash is separate, and finance leases remain despite no conventional borrowings. Q2 iDose sales were about $74M and Epioxa $11M, inside their disclosed franchises. Annual sales guidance is $680M-$700M, with Q3 corneal transition risk. Huntsville investment is expected to exceed $80M over multiple years.

The competing explanation

A launch can show strong reported growth while collections, access support, clinical work and construction consume cash. Reimbursement proposals can reduce treatment economics; existing cash and stock issuance can obscure the need for recurring self-funding.

Risks to track

Market-access decisions and claims processing affect adoption and collections.
Other surgical approaches compete for physician use.
Epioxa transition and product coding can disrupt corneal sales.
Clinical programs and research milestones require cash without guaranteed approvals.
Manufacturing expansion creates execution and capital-spending risk.
Stock compensation creates dilution even when added back in CFO.

Next checkpoints

Launch conversion · Each quarterly result (estimated). Separate iDose and Epioxa growth from other products and check receivable cash conversion.
Coverage changes · As payers publish decisions (estimated). Distinguish proposed policies from final and implemented access changes.
Manufacturing investment · Construction updates and cash statements (estimated). Compare actual Huntsville cash spending with the multi-year requirement.

Data coverage and open work

Product and geographic forecast splits are desk assumptions; rounded Q2 product disclosures are references, not exact standalone financial statements.
FY2026 nominal revenue guidance includes current FX assumptions. No unapproved pipeline revenue or automatic commercial benefit from proposed reimbursement policies is included.
Non-GAAP operating income retains ordinary stock compensation and acquired IPR&D. The approximately $15M Q2 award trigger is not mechanically repeated every quarter.
The new Huntsville facility is expected to require more than $80M over multiple years. Forecast construction timing is a sensitivity, not a disclosed annual budget; spending extends beyond this horizon.
Historical capex uses PP&E purchases; the separate 2025 real-estate purchase is outside that feed measure. Forecast capex includes assumed construction cash. Cash after other uses is before new financing or acquisitions.
No complete EPS, clinical trial probability, reimbursement-policy forecast or equity valuation is supplied. Sources are reviewed through September 19, 2026.

This review: First completed product-adoption, adjusted-to-GAAP and cash model including ordinary SBC, clinical expense and construction.

What the memory says

State as of the 2026-09-18 close: in a 120-day uptrend, above its 200-day, off the 52-week high, with overhead supply, heavy volume, closed strong, and some peers moving

300 similar days

Vs the market, in points	Low	Middle	High	Share up
1 session	-5.2	+0.1	+5.6	52%
5 sessions	-10.8	+0.4	+12.2	51%
10 sessions	-14.5	+0.9	+17.6	53%

Historical distributions of what followed similar states, measured before today's news. Not a forecast; no side.

Notes on this name

No published notes on this name yet.

Scorecard: 0 notes scored

Next report: 2026-10-27 (source: estimated from 10-Q filed 2026-07-29 plus 90 days)

Provenance

[1] reported: RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[2] derived: RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[3] reported: RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[4] reported: RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[5] reported: GrossProfit, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[6] derived: GrossProfit, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[7] reported: GrossProfit, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[8] reported: GrossProfit, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[9] reported: OperatingIncomeLoss, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[10] derived: OperatingIncomeLoss, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[11] reported: OperatingIncomeLoss, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[12] reported: OperatingIncomeLoss, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[13] reported: NetIncomeLoss, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[14] derived: NetIncomeLoss, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[15] reported: NetIncomeLoss, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[16] reported: NetIncomeLoss, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[17] reported: EarningsPerShareDiluted, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[18] reported: EarningsPerShareDiluted, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[19] reported: EarningsPerShareDiluted, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[20] reported: WeightedAverageNumberOfDilutedSharesOutstanding, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[21] reported: WeightedAverageNumberOfDilutedSharesOutstanding, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[22] reported: WeightedAverageNumberOfDilutedSharesOutstanding, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[23] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001558370-24-014295, 10-Q filed 2024-11-05; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[24] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[25] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001558370-25-006041, 10-Q filed 2025-05-01; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[26] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001558370-25-010113, 10-Q filed 2025-08-04; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[27] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[28] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[29] reported: CashAndCashEquivalentsAtCarryingValue, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[30] derived: NetCashProvidedByUsedInOperatingActivities, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[31] derived: NetCashProvidedByUsedInOperatingActivities, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[32] reported: NetCashProvidedByUsedInOperatingActivities, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[33] derived: NetCashProvidedByUsedInOperatingActivities, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[34] derived: PaymentsToAcquirePropertyPlantAndEquipment, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[35] derived: PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[36] reported: PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[37] derived: PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[38] derived: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment, accession 0001104659-25-104529, 10-Q filed 2025-10-31; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[39] derived: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-061944, 10-K filed 2026-02-23; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[40] derived: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-193004, 10-Q filed 2026-04-30; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json
[41] derived: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment, accession 0001193125-26-324201, 10-Q filed 2026-07-29; retrieved 2026-09-19T21:33:23+00:00 from https://data.sec.gov/api/xbrl/companyfacts/CIK0001192448.json

What the author read

July 29 10-Q: historical accounts, lease and facility commitments · retrieved 2026-09-19
July 29 results and annual sales outlook · retrieved 2026-09-19
July 29 quarterly review: product mix, corneal transition and SBC scope · retrieved 2026-09-19

Compiled 2026-09-19T21:33:23.957572+00:00 · authored fe802bef42cb · generated f3d6716ae287 · JSON

Daily notes · Scorecard